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Abstract 
The hormones atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are stored and secreted 
by cardiac myocytes. Recent studies have identified soluble N-ethyl-maleimide-sensitive-fusion 
attachment protein receptors (SNAREs) in the trafficking, docking and fusion of ANP and BNP secretory 
vesicles. In this study, I characterized the expression profiles of the three SNARE proteins (syntaxin 5A, 
syntaxin 18, and SNAP29), implicated in constitutive exocytosis, in atrial and ventricular cardiac 
myocytes.  My results suggest that syntaxin 5A, syntaxin 18 and SNAP29 are not important in the 
constitutive secretion of ANP and may play a role in another protein trafficking pathway. Syntaxin 1A and 
SNAP25, two SNARE proteins previously characterized in atrial cardiac myocytes, form a complex in 
adults that has been implicated in the exocytosis of ANP. I investigated the protein expression and 
promoter activity of these two SNARE proteins in neonatal and adult atrial and ventricular cardiac 
myocytes. The functional role of syntaxin 1A and SNAP25 was assessed using botulinum neurotoxin C 
(BoNT/C) and BoNT/A which cleave these SNARE proteins, respectively. Treatment of cardiac myocytes 
with BoNT/A and BoNT/C suggest that syntaxin 1A and SNAP25 regulate ANP secretion in neonatal 
cardiac myocytes, albeit low levels.  Lastly, I examined the influence of forskolin and phorbol myristate 
acetate (PMA) on the syntaxin 1A and SNAP25 promoter.  The lack of effect of these agents on gene 
reporter activity suggests that the CRE element in the syntaxin 1A and SNAP25 promoter do not 
significantly affect transcriptional activity. Overall, my studies demonstrate the developmental changes in 
SNARE protein expression in the heart, and their potential role in ANP secretion. 
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Introduction 
1.1 Natriuretic Peptides 
1.1.1 Background - Natriuretic Peptides 
The observation of granules within atrial cells in the early 1960s laid foundation for the discovery 
of the heart’s endocrine properties (Jamieson et al. 1964). Follow-up studies done by de Bold and 
colleagues (1981) found that these granules were important in salt and water homeostasis. By injecting 
extracts from the rat atria into the rodent’s bloodstream, de Bold and colleagues (1981) were able to 
stimulate salt excretion. These findings suggested the presence of a peptide important in regulating body 
fluid and electrolyte balance within the mammalian heart - a function that would have formerly been 
attributed to the kidney. In 1983, the purified 28-amino acid peptide was sequenced by Flynn and 
colleagues and pegged the "atrial natriuretic factor". In later years, the protein was re-named “atrial 
natriuretic peptide”, or ANP. 
Following the discovery of ANP, two structurally similar peptides, brain natriuretic peptide (BNP) 
and C-type natriuretic peptide (CNP) were discovered (Sudoh et al. 1988, Sudoh et al. 1990). Brain 
natriuretic peptide, originally discovered in the porcine brain, is a 32-amino-acid peptide. It possesses a 
similar function to ANP in holding both natriuretic and diuretic properties (Mukoyama et al. 1991), 
natriuresis being the excretion of salt and diuresis being the excretion of water. Both ANP and BNP are 
stored and secreted from granules within the main contractile cells of the heart, cardiac myocytes 
(Rushkoaho 2003). CNP, on the other hand, holds no natriuretic properties. It possesses two active 
forms: one which is 22-amino acids in length and the second which is 53-amino acids in length. Its 22-
amino acid form is most prevalent in the central nervous system (Levin et al. 1998), though CNP is also 
present in the vascular endothelium, functioning mainly to induce vasodilation and vascular growth (Suga 
et al. 1992).  
The common feature among all natriuretic peptides is a cysteine bridge connecting the peptides' 
17-amino acid ring (D’Souza et al. 2004). Although this segment is conserved amongst the family, the 
peptide sequence of each hormone varies across species. CNP is found to be the most conserved 
throughout evolutionary history. ANP is the most homologous across mammals and BNP is the most 
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variable (Clerico et al. 2006) among the three. In addition, two other peptides have also been identified as 
part of the natriuretic peptide family: DNP - a structurally similar peptide with vasodilative properties, 
produced by the venom of the green mamba snake (Schweitz et al. 1992), and urodilatin, a peptide 
produced by the kidney through alternative processing of pro-ANP (Schulz-Knappe et al.1998). The 
functional relevance of these peptides during cardiac stress has not been thoroughly investigated.  
 
1.1.2 Function of Natriuretic Peptides 
Natriuretic peptides affect a wide variety of organs including the central nervous system, kidney, 
peripheral vasculature, and adrenal glands. The main receptors at these target organs include: Natriuretic 
Peptide Receptor – A (NPR-A), NPR-B, and NPR-C.  
NPR-A and NPR-B are guanylyl cyclase receptors which convert guanosine triphosphate to the 
secondary messenger cyclic GMP (cGMP). The increased production of cGMP results in a signalling 
cascade targeting cGMP-dependent protein kinases (PKGs), cGMP-gated ion channels and cGMP-
regulated cyclic nucleotide phosphodiesterases (McGrath et al. 2005), which work together to induce the 
main effects of natriuretic peptides in their target organs. NPR-A is found to mediate most natriuretic 
effects of both ANP and BNP, with a higher affinity to the former. NPR-B has highest affinity to CNP, 
followed by ANP and BNP.  Both receptors are distributed at the major target organs - the kidney and 
adrenal glands, with NPR-A receptors focused in the main blood vessels and NPR-B receptors focused in 
the central nervous system (McGrath et al. 2005; Clerico et al. 2006). 
NPR-C is known as the clearance receptor. In contrast to NPR-A and NPR-B, it contains a 
fragment in its cytoplasmic portion characteristic of other clearance receptors (McGrath et al. 2005). Upon 
binding, NPR-C is internalized with its natriuretic peptide agonist via endocytosis. The peptide is then 
degraded in lysosomes and the receptor recycled back to the membrane. This receptor, in synchrony with 
the protease neutral endopeptidase (NEP), is responsible for the clearance of ANP and BNP. NPR-C is 
found in most target organs but is most abundant in the kidney and peripheral vasculature (Levin et al. 
1998; McGrath et al. 2005; Clerico et al. 2006).  
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The target organs of ANP and BNP work in synchrony to regulate blood pressure and blood 
volume, while maintaining proper salt-water balance. The response of these organs to an increase in 
preload serves as a useful example in demonstration of this property (Figure 1). When an increase in 
preload is detected via atrial stretch, plasma levels of natriuretic peptides rise resulting in several events 
including: a decrease in salt and water appetite, an increase in glomerular filtration rate in the kidney, a 
decrease in aldosterone release from the adrenal glands, and vasodilation in the peripheral vasculature. 
A decrease in sympathetic activity from the central nervous system also ensues, dampening baroreceptor 
activity (Levin et al.1998, McGrath et al. 2005). Natriuretic peptides have also been implicated in growth-
suppressing mechanisms. ANP has been found to inhibit hypertrophy and proliferation of vascular smooth 
muscle cells, while BNP has been found to inhibit myofibroblast formation (Pandey 2005; McGrath et al. 
2005). 
Clerico and colleagues (2006) describe the regulatory effect of natriuretic peptides as a balance 
between two states: a pro-inflammatory, pro-hypertrophic state in which sodium is retained, and an anti-
inflammatory, anti-hypertrophic state in which natriuresis and diuresis are favoured. Natriuretic peptides 
work in harmony with other systems such as the renin-angiotensin-aldosterone system, the vasopressin 
hormone system, and potent stimulators such as endothelin to maintain balance between these two 
states under normal physiological conditions. However, during chronic disease states, the balance is 
shifted to the pro-hypertrophic state. The difficulty in maintaining such a balanced system may be the 
reason why natriuretic peptides play such an important role in individuals enduring cases of heart disease 
and heart failure. 
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Figure 1. Function of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in target 
organs. When there is an increase in venous return, the atria of the heart undergo mechanical stretch. 
This results in an increase in ANP and BNP secretion. Once released, these peptides travel to their target 
organs eliciting a response that works in homeostasis to combat the original stimulus. In the central 
nervous system, there is a decrease in salt appetite, in the adrenal cortex – a drop in aldosterone, in the 
kidney – an increase in glomerular filtration rate, in the peripheral vasculature – vasodilation. These 
effects come together to decrease blood pressure and plasma volume, ultimately decreasing venous 
return. Reproduced with permission from Levin ER, Gardner DG, and Samson WK. Natriuretic peptides. 
New Engl J Med. 339(5): 321-328. Copyright © (1998), Massachusetts Medical Society. 
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1.1.3 Synthesis and Secretion 
1.1.3.1 ANP and BNP: Synthesis and Secretion 
The genes NPPA and NPPB, originally named “natriuretic peptide precursors” (NPP), encode the 
proteins ANP and BNP, respectively, and are found on chromosome 1 of humans (1 p 36) and 
chromosome 5 of rats. The two genes responsible for the two peptides contain three exons, with the 
peptide-encoding sequence residing on the second exon (McGrath et al. 2005). The release of these 
peptides begins with the transcription and translation of these genes. 
 The immediate form of ANP following translation is the pre-pro-ANP (1-151) peptide. Pre-pro-
ANP is cleaved by signal peptidase in the rough endoplasmic reticulum (ER) to its pro-ANP form (1-126) 
and stored in intracellular vesicles. Until signalled for release, ANP is stored in this form. Upon 
stimulation, these vesicles fuse to the membrane and release the protein in its pro-peptide form where it 
is cleaved by a serine protease, corin, on the plasma membrane of the myocyte. The resulting cleavage 
forms the N-terminal portion of the peptide, NT-proANP (1-98) and the biologically active form ANP (99-
126) (Figure 2a).  
The synthesis and secretion of BNP follows a similar pathway: NPPB is transcribed and 
translated to its pre-pro-BNP (1-134) form, then cleaved to pro-BNP (1-108) by signal peptidase in the 
rough ER. The underlying difference between the two peptides is that pro-BNP is cleaved to its N-
terminus portion (1-76) and its biologically active form BNP (77-108) in the trans-Golgi by the serine 
protease furin. The biologically active form is then stored in granules for regulated release (Rushkoaho 
2003) (Figure 2b). The storage of peptides in granules generally occurs in the atria. In the ventricle 
however, direct synthesis and secretion of ANP and BNP from their corresponding genes is what typically 
occurs. Once stimulated for release, granules storing ANP and BNP approach the membrane where they 
dock, fuse, and release the stored peptides via exocytosis. 
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Figure 2. Synthesis and secretion of ANP and BNP in cardiac myocytes. (a) Pre-pro ANP is 
transcribed and translated from the gene Nppa. The N-terminal of pre-pro ANP is then cleaved by signal 
peptidase in the endoplasmic reticulum (ER) to create pro-ANP which is stored in granules until signalled 
for release. Once stimulated for release, atrial granules are transported to the plasma membrane where 
they fuse and release the protein. ANP can either be released from this pool of granules or directly 
synthesized and secreted. Once the peptide is released, it is cleaved by serine protease corin on the 
plasma membrane into its biologically active form and it’s corresponding N-terminal peptide. (b) BNP is 
processed similarly to ANP. Its pro-BNP peptide, however, is cleaved by serine protease furin at the 
trans-Golgi to its N-terminus peptide and biologically active form. Both peptides are stored in granules 
with ANP or directly synthesized and released. 
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1.1.3.2 Mechanisms of Natriuretic Peptide Secretion 
Two methods of natriuretic peptide secretion have been outlined in the literature: constitutive 
secretion and regulated secretion. Constitutive secretion encompasses direct synthesis and secretion of 
the peptide wherein release occurs through passive diffusion. Regulated secretion, on the other hand, 
encompasses the stimulated release of natriuretic peptides via mechanical stretch or neuroendocrine 
factors such as endothelin-1 (ET-1) and angiotensin II (ANG II) (McGrath and de Bold 2005). 
Baseline levels of ANP and BNP are released from atrial cardiac myocytes directly after 
synthesis. It is hypothesized that a portion of newly synthesized peptide is secreted in small amounts 
immediately after synthesis, while the other portion is stored in vesicles for future release (McGrath et al. 
2005). Both hormones are stored together in vesicles, in their pro-peptide forms, until stimulated through 
hormonal or mechanical means.  
Mechanical stimulation, termed "stretch-secretion coupling", is defined as an increase in 
natriuretic peptide levels caused by atrial or ventricular wall stretch. This phenomenon occurs when a 
sharp increase in venous return results in an increase in cardiac volume and pressure. In response to this 
stimulus, pro-ANP and BNP are released from a depletable pool of granules within the atria (McGrath et 
al. 2005). ANP constitutes the major peptide released, while BNP is released at a lower rate. It is 
suggested that this rate correlates with the ratio of BNP stored with pro-ANP in granules (McGrath and 
deBold 2005).  A subset of BNP peptide, released post-mechanical stimulation may also be directly 
synthesized and secreted from the atria (Mantymaa et al.1993).  
“Sub-acute hemodynamic overload”, occurring post-overload, results in an increase in atrial ANP 
and BNP synthesis in the atria. In the ventricle, however, ANP and BNP mRNA levels do not change. An 
increase in ANP secretion from the atria is also observed, but because there is no additional release of 
BNP from the ventricle, an increase in BNP plasma levels is not observed (McGrath et al. 2005).  
Chronic overload results in direct synthesis and secretion of both ANP and BNP, observed in both 
atria and ventricle (McGrath et al. 2005). The most activity, however, is noted in the ventricle due to the 
chamber's larger size (Rushkoaho 2003). During normal physiological conditions, the amount of BNP 
stored is approximately 1-2% that of ANP, within atrial granules (McGrath et al. 2005). As a result, during 
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chronic overload, however, an increase in ANP is immediately observed, followed by the release of BNP 
after a short time lag. While a large amount of ANP is readily available in storage, BNP must first be 
synthesized and then secreted, mainly in the ventricle, to display any significant increases in plasma 
levels. Thus, BNP is known as a better indicator of cardiac disease as an increase in its plasma levels 
better reflects sustained volume and pressure overload (Rushkoaho 2003). 
 
1.1.3.3 Factors Regulating Natriuretic Peptide Secretion 
Endothelin-1, widely known as a strong vasoconstrictor, is the most potent stimulator of atrial 
natriuretic peptide secretion. When secreted by neighbouring endothelial cells, ET-1 has the ability to 
induce ANP secretion itself through binding to ETA receptors on cardiac myocytes. In addition, ET-1 has 
also been shown to augment the release of ANP induced by mechanical stretch. Angiotensin II (ANGII) 
also stimulates ANP secretion through binding to the AT-1 receptor on cardiac myocytes. In contrast to 
endothelin, which can stimulate natriuretic peptide on its own, it is not known whether the natriuretic 
effects of angiotensin II are direct or a result of its ability to increase atrial stretch. Nitric oxide, also 
released from endothelial cells, is a vasodilator. It opposes the effects of mechanical stretch and 
endothelin through the inhibition of ANP secretion. The effects of these factors in addition to several 
others such as adrenomedullin, prostaglandins, vasopressin, catecholamines, and adrenergic agonists 
are important in the regulation of volume and pressure homeostasis by natriuretic peptides  (Thibault, 
Amiri and Garcia 1999; Dietz 2005). In this study, endothelin-1 is used to stimulate regulated ANP 
secretion. 
 
1.1.4 Age-Dependent Secretion 
1.1.4.1 Fetal Expression of Natriuretic Peptides 
The expression of natriuretic peptides in the mammalian fetus surpasses that of the adult, with 
most transcriptional activity occurring in the ventricle. High fetal levels of ANP and BNP mRNA are found 
to decrease with development and drop to basal levels in adults. Although mRNA expression patterns 
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differ between the fetus and adult, ANP and BNP secretion occur in response to the same physiological 
stimuli: hypoxia, increased volume load, atrial stretch, and vasoconstrictors such as ET-1, ANGII, and 
phenylephrine. Thus, it is suggested that in both adult and fetal organisms, natriuretic peptides play a 
similar role in salt and water balance (Clerico et al. 2006). In addition, ANP in the human placenta and 
BNP and CNP in the mouse placenta have been suggested to promote vasodilation through the inhibition 
of vasoconstrictors and may assist in regulating blood supply to the fetus. It has also been suggested that 
natriuretic peptides play a role in regulating cardiac myocyte growth (ANP/BNP) and bone growth (CNP) 
during embryonic development (Cameron and Ellmers 2003). During embryogenesis in mice, ANP and 
BNP mRNA peak at certain crucial stages of development, indicating that ANP and BNP also play a role 
in the development of the heart (Cameron and Ellmers 2003). 
 
1.1.4.2 Neonate to Adult: Expression of Natriuretic Peptides 
Following birth, there is an age-dependent increase in ANP and BNP secretion levels in both 
women and men. Past research on healthy humans have found that higher levels of natriuretic peptides 
are found in women (Wang et al. 2002). This finding has also been observed in rodents, where an 
increase in natriuretic peptide gene expression occurs from neonatal stage to adult (Raizaida et al. 2000). 
This increase may reflect the characteristics an aging heart or occur as a result of a decrease in the 
clearance rate of natriuretic peptides with age (Clerico et al. 2006). Contrary to expression in the fetus, 
natriuretic peptide secretion post-birth is localized to the atria (Cameron and Ellmers 2003). 
 
1.1.5 Physiological Hypertrophy, Pathological Hypertrophy and Heart Disease 
At the cellular level, cardiac hypertrophy refers to an increase in the size of cardiac myocytes as a 
result of increased protein synthesis. In both physiological and pathological hypertrophy, this increase in 
cardiac myocyte growth is observed. However, the resulting physiological response to both types of 
hyertrophy differs between the two. 
During physiological hypertrophy, seen in exercise training (physical training, head-out water 
immersion) or pregnancy, an increase in venous return is sensed via mechanical stretch. The resulting 
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response is an acute increase in ANP and BNP secretion from stored granules within the atria. Because 
physiological hypertrophy is reversible and does not result in fibrosis or myocyte apoptosis (Bernardo et 
al. 2010), the response is short-lived. The typical acute response thus occurs wherein both natriuretic 
peptides work in a homeostatic fashion to combat the original stimulus. 
Pathological hypertrophy, however, is observed in disease states such as ischemia, myocardial 
infarction, and cardiomyopathies. It is often accompanied by myocyte death and fibrosis due to chronic 
volume and pressure overload (Bernardo et al. 2010). In response to pathological hypertrophy, certain 
fetal genes are re-expressed due to a phenomenon known as "fetal gene reprogramming". These genes 
include β-MyHC, α-skeletal actin as well as NPPA and NPPB, the genes coding for ANP and BNP. As a 
result, an increase in ANP and BNP synthesis in the ventricle is observed. The phenomenon of fetal gene 
reprogramming is characteristic of certain hallmark changes during pathology including cardiac 
remodeling and reversion to anaerobic metabolism (Rajabi et al. 2007). As a result, an increase in 
natriuretic peptide secretion from ventricular myocytes is observed. As natriuretic peptides are 
responsible for regulating blood pressure, changes in these peptides, their receptors, or their 
corresponding genes, may naturally lead to a physiological imbalance, which leads to heart disease in 
chronic cases. In addition to stimulating natriuretic peptide secretion through chronic wall stretch, 
pathological hypertrophy also results in the release of neuroendocrine factors such as ET-1, ANGII, and 
adrenergic receptor agonists which additionally assist in attenuating the original stimuli (Bernardo et al. 
2010). 
Phenylephrine, an α-adrenergic stimulator, and fetal bovine serum (FBS), a media supplement 
rich with growth factors, have been used in several studies to stimulate hypertrophy in vitro (Konhilas and 
Leinwand 2006; Frey et al. 2004; Simpson, McGrath and Savion 1982). These two factors are used in this 
study to compare two in vitro environments - primary myocytes grown at physiological conditions versus 
primary myocytes undergoing hypertrophy. 
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1.1.5.1 Fibroblasts 
The heart is comprised of four major cell types: cardiac myocytes, fibroblasts, endothelial cells, 
and smooth muscle cells. In addition to cardiac myocytes, fibroblasts have also been suggested to play a 
role in natriuretic peptide secretion. These cells are important in the deposition of collagen and scar 
formation. During hypertrophy, there is a switch in the phenotype of fibroblasts to their active form, 
myofibroblasts. This switch is stimulated by growth factors such as transforming growth factor beta (TGF-
β) or chemokines such as tumor necrosis factor alpha (TNF-α), which are released by neighbouring 
inflammatory cells in response to injury. Myofibroblasts are found to be more efficient than fibroblasts in 
creating a collagen framework. It is microfilaments within these cells that interact with extracellular 
fibronectin to create a stronger extracellular matrix (Baum and Duffy 2011). 
Previously it was thought that in non-myocyte cells, the promoter of NPPA (the gene encoding 
ANP) was repressed. As a result, all natriuretic peptide effects on non-myocyte cells were considered 
paracrine (Cameron et al. 2010). However, in 2010, Cameron and colleagues discovered that ANP is 
secreted from myofibroblasts when stimulated by TGF-β in adult sheep. A similar study done by Tsuruda 
and colleagues (2012) on adult canines found that stimulation of cardiac fibroblasts with TNF-α resulted in 
an increase in BNP secretion from fibroblasts. These two studies indicate the importance of fibroblasts in 
natriuretic peptide secretion during cardiac remodelling. Our current study uses TGF-β to induce 
myofibroblast formation in order to observe the molecular changes in fibroblasts during hypertrophy. 
 
1.2 SNARE Proteins 
1.2.1 SNARE Proteins and SNARE-associated Proteins 
The exocytosis of hormones is a complex process requiring a variety of proteins to assist at each 
step. The two universal components of this process include SNARE (soluble N-ethyl-maleimide-sensitive-
fusion-protein attachment protein receptors) proteins and SM (Sec1/Munc18-like) proteins. SNARE-
associated proteins such as complexins and synaptotagmin also assist in facilitating SNARE core 
complex formation and sensing calcium levels during exocytosis (Jahn and Scheller 2006). 
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 SNARE proteins are the key components in vesicular trafficking and exocytosis within the 
mammalian cell. They are localized to both intracellular granules and target membranes. The 
characteristic feature of SNARE proteins is a motif consisting of 60-70 amino acid heptad repeats which 
form an alpha helix. During exocytosis, SNARE proteins on both the vesicle and target membrane interact 
to form a stable complex facilitating the processes of docking, fusion, and release (Jahn and Scheller 
2006). This complex comprises four alpha helices which combine to form a coiled coil (Fasshauer et al. 
1998; Jahn and Scheller 2006). Originally, SNARE proteins were classified as v-SNAREs and t-SNAREs 
based on their location on the vesicle or target membrane, respectively. Later, they were classified into 
two new sub-types: Q-SNAREs and R-SNAREs, as their previous classification did not encompass 
vesicle-vesicle fusion. This new classification categorizes SNARE proteins by the main amino acid in its 
SNARE motif that contributes to the central ionic layer of each complex: Q-SNAREs contribute a 
glutamine residue and R-SNAREs contribute an arginine residue (Fasshauer et al. 1998). The most 
studied SNARE core complex consists of the three SNARE proteins: syntaxin, synaptosomal associated 
protein-25 (SNAP25) found on the plasma membrane, and vesicle-associated membrane protein 
(VAMP)/synaptobrevin found on the vesicle. In neuronal cells, syntaxin and VAMP contribute one alpha 
helix to the complex, while SNAP25 contributes two alpha helices (Chen and Scheller 2001). 
SM proteins also assist in the assembly of the SNARE core complex. Munc18, the best 
characterized SM protein, was originally known as a negative regulator of SNARE core complex 
formation. This protein binds to the N-terminus of syntaxin 1A on the membrane and interacts with its four 
alpha helices. One helix is made up of the SNARE motif, while the three remaining helices are made up 
of the Habc component of the syntaxin 1A gene. The Habc component is unique in that it is able to fold onto 
syntaxin 1A’s SNARE motif creating a “closed” conformation. Later, however, a new model was proposed 
in which SM proteins assist with vesicle fusion by interacting with the four alpha helices from the SNARE 
core complex, rather than syntaxin 1A alone, “clasping” them together. This “clasp” functions to keep 
SNARE proteins from moving between the vesicle and membrane during fusion (Shen et al. 2007;Sudhof 
and Rothman 2009). In addition, SM proteins were also suggested to stimulate the mixing of 
phospholipids at the membrane inducing a change in curvature and creating an ideal environment for 
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fusion (Carr and Rizo 2010). It should be noted however that SNARE proteins are capable of inducing 
membrane fusion without the assistance of SM proteins (van den Bogaart et al. 2010). 
Although SNARE proteins alone can mediate fusion, the fast, regulated release of certain 
secretions such as neurotransmitter release relies on an influx of calcium. Synaptotagmin-1, a 
transmembrane protein found on vesicles, functions as a calcium sensor, interacting with both calcium 
and SNARE proteins during exocytosis. It has two calcium binding sites called C2 domains. When 
calcium is bound to these domains, synaptotagmin-1 facilitates the assembly of the SNARE core complex 
through calcium-dependent phospholipid binding and/or calcium-dependent SNARE complex binding. In 
both scenarios, synaptotagmin binding allows for the formation of a vesicular pore following fusion of the 
vesicle to membrane (Chapman 2002). 
Complexins, another class of regulatory protein, have been found to function alongside 
synaptotagmin in regulating the formation of the SNARE core complex. Two leading researchers in 
vesicle trafficking, Rothman and Sudhof, propose different functions for complexins (Brose 2014): 
Rothman and colleagues suggest that complexins function as a reversible clamp, preventing the SNARE 
complex from forming until synaptotagmin senses calcium and displaces complexin, allowing for fusion 
(Giraudo et al. 2006). In contrast, Sudhof and colleagues believe complexins to be a co-factor of 
synaptotagmin, assisting in the priming of SNARE complexes prior to vesicle fusion (Reim et al. 2001). 
 
The general assembly of the SNARE core complex is briefly outlined below: Once packaged by 
the Golgi apparatus, proteins within the cell are trafficked to their main destination via large dense core 
vesicles. Membrane-targeted proteins are sent to the membrane where the SNARE core complex forms 
with the assistance of SM proteins, synaptotagmin and complexins. The generally accepted “zipper” 
model suggests that Q-SNAREs found on the membrane cluster together to form an “acceptor complex”. 
Once the incoming vesicle approaches, R-SNAREs found on the vesicle interact with Q-SNAREs, each 
interacting at their SNARE motifs to form a coiled coil alpha-helical complex. This results in the formation 
of a trans-complex, driving the vesicle to closer proximity with the target membrane. In agreement with 
the “force” model, a mechanical force from the linker region of the SNARE proteins is exerted onto the 
membrane overcoming the energy barrier required for the vesicle to fuse with the membrane. The result 
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is the formation of a pore and the exocytotic release of the vesicles’ contents. Finally, the SNARE 
proteins reassemble into a cis-complex following exocytosis, in which all SNARE proteins reside on the 
same side of the membrane (Jahn and Scheller 2006) (Figure 3). 
The dissociation and recycling of SNARE proteins post-fusion is facilitated by the ATPase, NSF 
(N-ethyl maleimide-sensitive factor) and the adaptor proteins, SNAPs (soluble NSF attachment proteins) 
which bind to the cis-SNARE complex, providing the metabolic energy for disassembly. The interaction of 
NSF and SNAPs with SNARE proteins is what originally inspired the “SNARE” name (Jahn and Scheller 
2006). 
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Figure 3. Role of SNARE proteins, SNARE-associated proteins, and SM proteins in neuronal 
exocytosis. 
Before vesicle docking, SM protein Munc18 interacts with SNARE protein syntaxin, keeping it in closed 
conformation. During neuronal exocytosis, neurotransmitters are packaged in vesicles and transported to 
the membrane from the Golgi.  Upon vesicle approach, Munc18 releases syntaxin. This allows syntaxin, 
SNAP25 on the membrane, and synaptobrevin/VAMP on the vesicle, to interact, bringing the vesicle 
closer to the membrane where it docks. When stimulated for release, there is an influx of calcium which is 
sensed by synaptotagmin. With the help of complexins, synaptotagmin binds to the SNARE proteins 
facilitating the formation of a trans-SNARE complex. This allows the vesicle to fuse to the membrane 
creating a pore for neurotransmitters to be released. At this point, the trans-SNARE complex reassembles 
into a cis-SNARE complex, which is later disassembled by NSF and SNAP proteins. Reprinted from 
Brose, Nils. All roads lead to neuroscience. Neuron. 81(4):.723-727. Copyright © (2014), with permission 
from Elsevier. 
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1.2.2 SNARE proteins in the brain 
Although the discovery of SNARE proteins in the mammalian system began in the brain, it was 
the study of vesicular transport in yeast that led to the identification of the SNARE binding partners NSF 
and SNAP in the brain. In 1979 to 1980, Novick and Schekman identified sec genes in yeast that when 
mutated, resulted in the accumulation of vesicles within its cells. Under the supervision of Dr. James 
Rothman, the mammalian homologues of the two SEC proteins, SEC18 and SEC17, were identified: N-
ethylmaleimide sensitive factor (NSF) and soluble NSF-attachment protein (SNAP) (Block et al. 1988; 
Clary et al. 1990). This finding proved crucial to the study of SNARE proteins in the brain as it was due to 
the abundance of these two proteins in the brain that the discovery of their binding partners, and 
consequently the first SNARE proteins, were identified. These include: VAMP/synaptobrevin, syntaxin, 
and SNAP25 (Brose 2014). These proteins were later established as the three main SNARE proteins of 
the canonical SNARE core complex, well-studied in neurotransmitter release, while NSF and SNAP were 
found to disassemble the complex post-vesicle fusion (Söllner et al. 1993).  Synaptobrevin/VAMP was 
found to localize to synaptic vesicles, while syntaxin and SNAP25 were found to localize to the 
presynaptic membrane. The relevance of these proteins to membrane fusion was further corroborated 
through the demonstration that Clostridial neurotoxins, which proteolytically cleave specific SNARE 
proteins, impair neurotransmitter release (Montecucco and Schiavo 1995). Since then, the 
characterization of SNARE proteins and SNARE-associated proteins have been widely studied using 
neuronal SNARE proteins as a model.  
 
1.2.2.1 Clostridial Neurotoxins 
Clostridial neurotoxins are a family of zinc endopeptidases isolated from the anaerobic bacteria 
Clostridium tetani and Clostridium botulinum. These toxins target and cleave specific SNARE proteins 
involved in neuronal exocytosis, impairing neurotransmitter release. Tetanus neurotoxin (TeNT), 
produced by Clostridium tetani, blocks neurotransmission in the inhibitory interneurons of the spinal cord, 
while serotypes of botulinum neurotoxins (BoNTs), produced by Clostridium botulinum, block 
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acetylcholine release at the neuromuscular junction. Administering both toxins individually results in 
paralysis (Montecucco and Schiavo 1995).  
When administered, BoNT and TeNT interact with gangliosides on the lipid membrane before 
binding to an unknown, high affinity receptor, allowing it to be internalized into intracellular vesicles via 
endocytosis. TeNT travels down the axon to inhibitory interneurons while BoNTs remain in the 
neuromuscular junction. Once internalized, the inside of the intracellular vesicle undergoes acidification, 
and the BoNTs within undergo a structural change. The light chain of the BoNT, which contains its zinc 
endopeptidase, is released from the vesicle. In the cytosol, the light chain proteolitically cleaves its target 
SNARE (Turton et al. 2002). The target proteins are as follows: TeNT, BoNT B, D, F, and G cleave 
VAMP/synaptobrevin; BoNT A, C and E cleave SNAP25; and BoNT C cleaves syntaxin 1 (Turton et al. 
2002) (Figure 4). SNARE cleavage has been found to inhibit fusion, but not the binding of vesicles to the 
presynaptic membrane (Weber et al. 1998).  
Botulinum toxins have proven to be a crucial tool in characterizing neuronal SNARE proteins. 
However, they have yet to be used in characterizing SNARE proteins in the heart as this area of research 
is still in its infancy. In our study, we transfect neonatal atrial and ventricular rat cardiac myocytes with 
plasmids containing DNA for botulinum toxins A and C. The cleavage sites are as follows: BoNT/A 
cleaves SNAP25 at Gln177 and Arg176, while BoNT/C cleaves syntaxin 1A at Lys253 and Ala254 
(Sutton et al. 1998).  
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Figure 4. Role of botulinum neurotoxins in the cleavage of SNARE proteins syntaxin, SNAP25, and 
VAMP/synaptobrevin. The target proteins of botulinum neurotoxins are as follows: syntaxin is cleaved by 
BoNT/C, SNAP-25 is cleaved by BoNT/C, BoNT/A, and BoNT/E and VAMP/synaptobrevin is cleaved by 
Tent, BoNT/B, BoNT/G, BoNT/D, and BoNT/F. Reproduced from: “Presynaptic CNTs targets" by Y tambe 
- Own work. Licensed under Creative Commons Attribution-Share Alike 3.0 via Wikimedia Commons - 
http://commons.wikimedia.org/wiki/File:Presynaptic_CNTs_targets.svg#mediaviewer/File:Presynaptic_CN
Ts_targets.svg. (Accessed on: July 20,2014) 
19 
 
1.2.3 SNARE proteins in the heart 
Formerly, SNARE proteins were most commonly known for regulating the release of 
neurotransmitters. It was in the last decade that the importance of SNARE proteins in the heart was 
discovered through the exocytotic release of the hormone, atrial natriuretic peptide. In 2006, Peters and 
colleagues identified two sets of SNARE complexes involved in regulating exocytosis in rat atrial 
myocytes - one in neonatal and adult mice and one solely in adults. Using confocal microscopy, they 
were able to observe that certain SNARE proteins co-localize with ANP granules. The first complex which 
was found to co-immunoprecipitate with VAMP-2, consisted of synaptotagmin, syntaxin 4 and SNAP23. 
The second complex which also co-immunoprecipitated with VAMP-2, consisted of synaptotagmin, 
syntaxin 1, and SNAP25. VAMP-1’s association with VAMP-2 was also demonstrated using confocal 
microscopy. Using cell fractionation, in addition to confocal and fluorescent microscopy, the authors were 
also able to conclude that these SNARE proteins co-localize with ANP-containing granules (Peters et al. 
2006). This novel finding suggested that SNARE proteins play a role in ANP secretion. 
In 2010, Ferlito and colleagues looked further into the functional significance of syntaxin 4, 
VAMP-1 and VAMP-2 in terms of ANP secretion. Using siRNA techniques, they knocked down the three 
SNARE proteins individually resulting in a significant decrease in ANP release after stimulation with 
endothelin-1. It was noted that although ANP levels decreased, these levels did not fall below baseline. It 
was concluded that this neonatal complex must play a role in the regulated release of ANP and that 
constitutive release of ANP must be regulated by a different SNARE complex. 
Besides the role of SNARE proteins in exocytosis, SNARE proteins have recently been found to 
play a role in regulating ATP-sensitive potassium channels (KATP) as well as voltage gated potassium 
channels (Kv). In 2011, Chao and colleagues found that syntaxin 1 interacts with cardiac potassium 
channels in regulating the excitability of the heart. Characteristics of cardiac stress include a decrease in 
pH (due to an accumulation of acidic by-products from anaerobic glycolysis) as well as a decrease in 
ATP. The decrease in pH and ATP results in the opening of KATP channels and could result in arrhythmias 
of the heart. In response to these stressors, a change in the interaction of syntaxin with SUR2A subunits 
of KATP channels was observed. Chao and colleagues proposed that at high ATP levels, KATP channels 
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are closed, but during cardiac stress, the ATP:ADP ratio decreases and syntaxin 1A acts on SUR2A by 
binding to its subunits and opening the channel, allowing potassium to enter. This regulatory role has also 
been proposed for syntaxin 1A and SNAP25 in relation to other Kv channels. 
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1.2.4 Transcriptional Control of SNARE Proteins 
It was previously shown in rats that syntaxin 1A and SNAP25 protein levels are only expressed in 
adult atrial cardiac myocytes (Peters et al. 2006). However, the transcriptional activity of these proteins 
has yet to be determined in both the atria and ventricle. The main SNARE proteins examined in this study 
include: syntaxin 1A and SNAP25.  
 
1.2.4.1 Syntaxin 1A - Overview 
Although the promoter region has yet to be characterized, the mRNA transcript of syntaxin 1A 
has been sequenced in many mammals, specifically, humans and rats. Syntaxin isoforms include but are 
not limited to: syntaxin 1A and syntaxin 1B. While the different isoforms have several functions in other 
tissues, syntaxin 1A and 1B complete specific functions in calcium-dependent neurotransmitter release in 
the brain (Bennett et al. 1993).  
Syntaxin 1A expression is mostly localized to the brain, but is also present in beta cells of the 
islets of Langerhans (Lam et al. 2005), immune cells such as lymphocytes (Nakamura et al. 2003), and 
more recently in cardiac myocytes (Peters et al. 2006). Syntaxin 1A contains a cytoplasmic region in its 
first 265 residues and a transmembrane domain that makes up the next 266-288 residues (Fernandez et 
al. 1998). The N-terminal domain, spanning from the 28th-144th residue, is suggested to play a crucial 
role in exocytosis. This domain has many functions including interaction with SM proteins such as Munc 
18, blocking the formation of the SNARE core complex itself, and interactions with other regulatory 
components such as synaptotagmin (Fernandez et al. 1998). The many functions of the syntaxin 1A N-
terminus are still under investigation. 
 
1.2.4.2 SNAP25 - Overview 
The SNAP25 mRNA sequence has been characterized in humans, mice, chicken, zebrafish, C. 
elegans, and Drosophila. In the mouse brain, two transcriptional start sites were characterized on the 
SNAP25 gene, 42 nucleotides apart. Its promoter region, 2073bp upstream of the first transcriptional start 
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site, contains the following elements: a CRE recognition sequence -11 to -18bp, a TATA box -26bp, three 
SP1 sites -100bp, three AP-1 binding sites -600bp, and two TG repeats at 0bp and -1490bp. In chicken, 
however, the SNAP25 promoter contains all elements except for the CRE element (Ryabinin et al. 1996). 
In terms of development, SNAP25 mRNA is found to be expressed at low levels in both the 
embryo and the early neonatal stages within the cell bodies of neurons. Expression levels increase during 
the development of the brain and during synaptogenesis (Bark et al. 1995). Oyler and colleagues (1991) 
studied the brain of adult rodents and found that SNAP25 is synthesized in the cell body of neurons, then 
transported across the axon until it is ready to be relocated to the presynaptic neuron. Some studies 
suggest that SNAP25 plays a role in neurite elongation (Kimura et al. 2003). While SNAP25 is mostly 
found in the brain, it is also found at lower levels in other endocrine tissues such as the beta-cells of the 
pancreas (Ryabinin et al. 1996, Sadoul et al. 1995). 
There are two isoforms of SNAP25, formed through alternative splicing at the fifth exon: SNAP25-
a and SNAP25-b. SNAP25-a is localized to neuroendocrine cells and developing axons and it has been 
suggested that it is responsible for trafficking vesicles containing the components necessary for axonal 
growth. SNAP25b, on the other hand, is localized to central and peripheral neurons and thought to take 
part in the canonical function of neurotransmitter release. The presence of two SNAP25 isoforms 
indicates that post-transcriptional processing may be important in regulating SNAP25’s function, whether 
it be secretion or assisting in the vesicular transport of materials important to the growth of the cell (Bark 
et al. 1995). 
 
1.2.4.3 Transcriptional Activity of SNAP25 in Ovarian Cells 
In 2007, Shimada and colleagues looked at the transcriptional activity of SNAP25 in ovarian 
mouse cells in an attempt to investigate the molecular mechanisms controlling its expression during 
exocytosis. They transfected granulosa cells with a -1517bp SNAP25 promoter-luciferase reporter, as 
well as truncated versions of the promoter without certain regulatory regions, to pinpoint the exact regions 
necessary for activity of SNAP25. By stimulating the transfected granulosa cells with forskolin/phorbol 12-
myristate 13-acetate (FOR/PMA), stimulators of cAMP and protein kinase C (PKC) respectively, they 
23 
 
found that the presence of the SP1/SP3 regulatory region, TATA box, and CRE site on the promoter were 
necessary for SNAP25 promoter activity. 
This study was replicated by David Boyce, a former undergraduate thesis student of Dr. Robert 
Tsushima, in cardiac myocytes. He found that the minimal promoter length for SNAP25 expression in 
atrial and ventricular cardiac myocytes contains the TATA box, a sequence typically found in 
housekeeping genes, and the transcriptional element CRE, found to be important in intracellular calcium 
signalling (Mao et al. 2007)(Figure 5). David Boyce postulated that cAMP, stimulated by forskolin, is 
linked to the calcium-mediated secretion of ANP due its activity upstream of CRE activation. cAMP 
activates PKA which interacts with calcium response element-binding proteins (CREB) in the nucleus, 
which ultimately binds to CRE (Vallejo 1994). Previous studies have found that an increase in intracellular 
Ca2+ signalling leads to the increased phosphorylation of CREB through PKC, and increased binding of 
CRE (Mao et al. 2007). Thus, stimulation of both cAMP and PKC in cardiac myocytes should theoretically 
increase binding of CRE on the SNAP25, and possibly syntaxin 1A promoter, raising its rate of 
transcription and corresponding protein levels, and ultimately raising ANP secretion levels.  
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Figure 5. The minimal promoter length required for SNAP25 promoter activity contains a TATA 
box and the CRE element. HL-1 and H9c2 cell lines, models for atrial and ventricular cardiac myocytes 
respectively, require a minimum promoter length of -41 kb for transcriptional activity to occur. HL-1 cells 
display greater promoter activity than H9c2 cells. Figure adapted from Boyce, D. 2013. Regulation of 
SNAP-25 promoter activity in cardiac myocytes. Biology Honours Thesis. York University: Toronto, 
Ontario. 
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1.3 SNARE Proteins in Constitutive Secretion 
1.3.1 Syntaxin 5A, syntaxin 18 and SNAP29 are important in constitutive secretion within 
mammalian cells 
Despite the vast amount of research done on natriuretic peptides, the mechanisms involved in 
their secretion are still vague. Although some studies have suggested certain SNARE complexes to be 
involved in the regulated ANP secretion pathway (Ferlito et al., 2010; Dietz 2005), the specific SNARE 
proteins involved in the constitutive pathway still remain unknown. Furthermore, the SNARE proteins 
responsible for BNP secretion have yet to be explored. 
In 2010, Gordon and colleagues performed a screen in which they silenced 51 SNARE and 
SNARE-associated proteins in HeLa cells. These HeLa cells were transfected with a reporter construct 
containing a GFP-coding region. This reporter construct contains a gene that when synthesized, creates 
mutant FKBP proteins which form dimers that aggregate at the ER. When the corresponding cell is 
stimulated with its ligand (AP21998), the dimer solubilizes and can be secreted. The amount of 
fluorescence was measured using a flow cytometer. The greater the fluorescence, the more dimer has 
accumulated; the lower the fluorescence, the more constitutive secretion has occurred. 
This mass screen identified many SNARE proteins associated with constitutive secretion. Three 
SNARE proteins were chosen out of the 51 identified to analyze the different components of the vesicle 
trafficking pathway: syntaxin-5A, syntaxin-18, and SNAP29. Their role in constitutive ANP and BNP 
secretion is investigated in this study. Previous studies implicate syntaxin 5A in anterograde transport 
from the ER to Golgi (Dascher et al. 1994), syntaxin 18 in retrograde transport from the Golgi to the ER 
(Iinuma et al. 2009), and SNAP29 in post-Golgi transport (Su et al. 2001) (Figure 6). 
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Figure 6. Localization of SNARE and SNARE-associated proteins implicated to play a role in the 
constitutive secretion pathway. The SNARE proteins indicated above were found by Gordon and 
colleagues (2010) to be important in constitutive secretion within the mammalian cell. Syntaxin 5 (STX5), 
syntaxin 18 (STX18) and SNAP29 were chosen for study to represent each segment of the secretory 
pathway. Syntaxin 5 is found to play a role in anterograde transport of vesicles from the endoplasmic 
reticulum to the Golgi, syntaxin 18 is found to assist with retrograde transport from the Golgi to the 
endoplasmic reticulum, and SNAP29 is found to assist with Golgi to plasma membrane transport. 
Reprinted from Gordon DE, Bond LM, Sahlender DA, and Peden AA. A targeted siRNA screen to identify 
SNAREs required for constitutive secretion in mammalian cells. Traffic. 11(9): 1191-1204. Copyright © 
(2010), John Wiley & Sons, Inc. 
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1.4 Hypotheses 
1.4.1 Developmental changes in SNARE protein expression in the heart 
The first aim of this study is to characterize the age-dependent expression profiles of syntaxin 5A, 
syntaxin 18, SNAP29, as well as the natriuretic peptides ANP and BNP using neonatal (1 day, 7 day, and 
14 day) and adult rat models. As the ventricle is known to be the main site of constitutive secretion (Bloch 
et al. 1986), an increase in the expression of these three SNARE proteins is expected in the ventricle 
compared to the atria. Fibroblasts as well as 1 day and 7 day neonatal ventricular myocytes, were studied 
with the goal of observing any differences in SNARE expression across cell types or development.  
ANP and BNP plasma levels both increase with age. With this in mind, it is speculated that a 
greater amount of vesicles are required for the transport of these natriuretic peptides as well as a greater 
demand for the machinery involved in their exocytosis. As a result, I hypothesize syntaxin 5A and 
SNAP29 expression levels to increase in both atria and ventricles during development, as there would be 
a greater need for anterograde transport from the ER to the Golgi and similarly from the Golgi to the cell 
membrane. Additionally, I would hypothesize syntaxin 18 expression levels to decrease during heart 
development as less recycling of vesicles and degradation would be required.  
Building on this idea, the second aim of this project was to look at the expression of these 
SNARE proteins in response to pathological hypertrophy. During hypertrophy, there is a significant 
increase in constitutive natriuretic peptide secretion from the ventricle. This increase is noted in the 
literature in both cardiac myocytes (McGrath et al. 2005, Rushkoaho 2003) as well as fibroblasts 
(Cameron et al. 2000). Our study aims to induce hypertrophy in both these cells and observe whether the 
expression of these SNARE proteins follow the trends we expect. Consistent with my previous 
hypothesis, I would expect the previously described SNARE proteins to behave similarly in neonatal 
ventricular myocytes post-drug treatment. With an increase in ANP and BNP post-drug treatment, I 
expect to see an increase in syntaxin 5A and SNAP29 protein expression, as well as a decrease in 
syntaxin 18. I would expect that the trends in expression observed with hypertrophy should be more 
exaggerated than that observed with age, as the increase seen in ventricular natriuretic peptide synthesis 
and secretion is much more pronounced. 
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1.4.2 Syntaxin 1A and SNAP25 expression and promoter activity will be higher in the atria 
versus ventricle and higher in adults versus neonates. 
As previously stated, Peters and colleagues (2006) identified two complexes of SNARE proteins 
responsible for ANP secretion in atrial myocytes. The first consisted of SNAP23, syntaxin 4, VAMP-1, and 
VAMP-2.  Although a follow-up study was done on this complex, the second complex consisting of 
syntaxin 1A, SNAP25, VAMP-1 and VAMP-2, did not incite further research. The third aim of this study to 
characterize the age-dependent expression profiles of syntaxin 1A and SNAP25 in neonatal and adults 
using immunoblotting, as well as their transcriptional activity using a secreted luciferase assay at 1 day 
and 7 days of age. Previous work done by Xiaodong Gao in the Tsushima lab characterized syntaxin 1A 
and SNAP25 protein levels in atrial tissue and found that in addition to being expressed in adults, both 
proteins were also expressed in neonatal cells and increased with age (Figure 7). Looking at promoter 
activity in both 1 day and 7 day cells may provide insight into the activity of these SNARE proteins at the 
neonatal stage. It is peculiar that a second set of SNARE proteins are required in the adult heart when 
both neonatal and adult hearts already consist of the SNARE protein complex consisting of SNAP23 and 
syntaxin 4. I hypothesize that with an increase in natriuretic peptide levels seen with age, the additional 
appearance of a second regulatory complex is required to assist with the increased amount of natriuretic 
peptide secretion. Both transcriptional activity and protein levels should be reflective of this increase.  
The chamber specific expression of syntaxin 1A and SNAP25 was also investigated in this study. 
Previous work done by Xiaodong Gao in the Tsushima lab characterized these two SNARE proteins in 
atrial tissue (Figure 7). However, the differences in chamber expression between atrial and ventricular 
tissue have not been compared on the protein or transcription level. The fourth aim of this project is to 
characterize the chamber-specific expression of syntaxin 1A and SNAP25 protein levels and 
transcriptional activity in atrial and ventricular tissue and cells. I hypothesize that I will see a bigger 
increase in expression within the atria, as this is the main site of natriuretic peptide secretion under 
normal physiological conditions. 
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Figure 7. Expression profiles of syntaxin 1A, syntaxin 4, SNAP25, SNAP23, pre-pro-ANP, and α-β-
tubulin in 1 day, 7 day, 14 day, and adult atrial tissue probed by Western blot (work conducted by 
Xiadong Gao, lab technician of Dr. Robert Tsushima’s lab). A general increase in syntaxin 1A and 
SNAP25 protein levels is observed with age. In contrast, there is relatively no change in syntaxin 4 and 
SNAP23 expression from 1 day to adult rat atrial tissue. The increase in syntaxin 1A and SNAP25 
expression corresponds with an increasing trend in protein levels observed in pre-pro-ANP with age. 
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The age-dependent and chamber-specific protein expression profiles of syntaxin 1A and SNAP25 
will be studied using immunoblotting.  In terms of transcriptional activity, neonatal atrial and ventricular 
cardiac myocytes will be transfected with syntaxin 1A and SNAP25 promoters and the secreted luciferase 
product measured using a luminometer. 
Furthermore, I will investigate the functional role of these two SNARE proteins in ANP secretion 
by transfecting neonatal cardiac myocytes with DNA for botulinum neurotoxin type A and botulinum 
neurotoxin type C to cleave SNAP25 and syntaxin 1, respectively, in both atrial and ventricular cardiac 
myocytes. Following this, I will measure ANP secretion after stimulating cells with endothelin-1. 
Neurotoxin efficiency will be confirmed using Western blot. If these SNARE proteins are indeed important 
in natriuretic peptide secretion, cleaving these SNARE proteins should result in decreased ANP levels 
within the media. 
 
1.4.3 Treatment of transfected myocytes with FOR/PMA will increase syntaxin 1A and SNAP25 
promoter activity by increasing binding to the CRE promoter element. 
Lastly, I endeavoured to support the work of David Boyce in the Tsushima lab by looking into the 
importance of the CRE element in SNAP25 transcriptional activity. Neonatal cardiac myocytes initially 
transfected with syntaxin 1A and SNAP25 promoters were treated with forskolin/PMA (FOR/PMA) to 
increase CREB binding to CRE within the nucleus. Forskolin increases cAMP activity, ultimately leading 
to downstream CRE binding (Vallejo 1994). PMA stimulates PKC which increases phosphorylation of 
CREB and also CRE binding (Mao et al. 2007). As a result, treatment with FOR/PMA should 
hypothetically increase binding of CRE on the SNAP25 and possibly syntaxin 1A promoter, raising its 
corresponding transcriptional activity within the nucleus.  
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Methods 
2.1 Cell Culture & Isolation 
2.1.1 Cell lines (HL-1, H9c2, and MIN6) 
Cells were plated to 10 mm dishes in their corresponding media. The plating media were as 
follows: HL-1 media - Claycomb Medium (Cat. #51800C - Sigma-Aldrich) supplemented with 10% fetal 
bovine serum (FBS) (Cat. #12483-020, Life Technologies), 1% penicillin/streptomycin (P/S) (Cat. #15140-
122), 1% norepinephrine (NorEpi), and 1% L-glutamine; H9c2 media - F12/Dulbecco Modified Eagle 
Medium DMEM) (Cat. #319-085-CL - Wisent Inc.) supplemented with 10% FBS, 1% P/S; MIN6 cell media 
– DMEM (Cat. #319-005-CL - Wisent Inc.) supplemented with 1.7 μL of 14.3M of β-mercaptoethanol 
(Cat.#M6250-ALDRICH, Sigma-Aldrich), 10% FBS, and 1% P/S. HL-1 dishes and/or flasks were pre-
coated with 0.02% gelatin and 200 mL fibronectin 24 hours before plating. Cells were then incubated and 
maintained at 37°C in 5% CO2. 
 
2.1.2 Primary cardiac myocytes 
 All research conducted on animals was approved by York University’s Animal Care Committee, 
and was conducted in accordance to the guidelines of the Canadian Council on Animal Care.  Neonatal 
atrial and ventricular cardiac myocytes were isolated from Sprague-Dawley rats at 1 day, 7 day and 14 
days. Hearts were excised and washed in sterilized Ca2+- and bicarbonate-free HEPES-based Hanks 
(CBFHH) Buffer consisting of 137mM NaCl, 5.36 mM KCl, 0.81 mM MgSO4, 5.55 mM dextrose, 0.44 mM 
KH2P04, 20.06 mM HEPES, 0.34 mM NaH2PO4, pH 7.4. Stock solution was stored at 4°C, diluted, filtered 
and brought to room temperature before use. 
Both atria and ventricle were separated for isolated digestion. Tissues needed for immunoblotting 
were frozen in liquid nitrogen for homogenization at a later date. Tissues undergoing digestion were 
minced into small pieces and trypsinized using 300 mg of trypsin 1:250 (Cat. #27250018, Gibco) diluted 
in 200 mL of CBFHH. Trypsinization comprised of twelve to sixteen five-minute washes in 10 mL of the 
above-mentioned dilution. All washes took place at 37°C within a water bath. After tissue was completely 
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digested, the supernatant from each wash was collected and combined with 7 mL FBS in 50 mL tubes 
until tubes were filled. The enzymatic solution combined with FBS was then spun at 1500 rpm for 5 
minutes. The resulting cell pellet was re-suspended in 6 mL of F12/DMEM medium with 10% FBS and 1% 
P/S. Cells were re-plated to one 10 mm dish per 50 mL tube of solution and incubated for 45 minutes at 
37°C. Finally, the cells were combined and spun at 1500 RPM for 5 minutes. The resulting pellet was re-
suspended in the media indicated above, re-plated, and maintained at 37°C in 5% CO2. 
 
2.1.3 Primary fibroblasts 
Primary fibroblasts and immortal cell lines were passaged once 80% confluency was reached. 
Medium was removed and cells were rinsed with phosphate buffer saline (PBS). 2 mL of 0.5% sterilized 
trypsin was then added to the dish and incubated for 5-10 minutes until cells were dislodged from the 
plate. The trypsinized cells were then removed and 3 mL of corresponding media combined to neutralize 
the enzyme. The enzymatic solution was then spun at 1500 rpm on a Thermo Scientific Sorvall Legend T 
Plus/RT Plus Centrifuge (Thermo Fisher Scientific, Waltham MA, USA) for 5 minutes. Following the spin, 
the supernatant was removed into a waste beaker. The resulting cell pellet was re-suspended in its 
corresponding media and re-plated to a new 10 mm dish or flask. 
 
2.1.4 Cell Treatment 
2.1.4.1 Probing for syntaxin 5A, syntaxin 18, SNAP29 – Control vs. Hypertrophy-induced cells 
24 hours following isolation, 7 day neonatal ventricular cardiac myocytes were treated as follows: 
Cardiac Myocytes 
Control Group 
 
Hypertrophy treatment 1 
 
Hypertrophy treatment 2 
 
DMEM/F12 media supplemented with 1% ITS and 1% P/S 
 
DMEM/F12 media supplemented with 100 μM phenylephrine 
 
DMEM/F12 media supplemented with 10% FBS and 1% P/S 
Cardiac Fibroblasts 
Control group 
 
Hypertrophy treatment 1 
DMEM/F12 media supplemented with 10% FBS and 1% P/S 
 
DMEM/F12 media supplemented with 10% FBS, 1% P/S, and 50 
ng/mL transforming growth factor-β (TGF-β) 
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 Cells were treated for 48 hours then harvested to allow sufficient time for drug-treatment to elicit a 
response. 
2.1.4.2 Probing for syntaxin 1A, SNAP25 and pre-pro-ANPs 
24 hours following isolation, 1 day and 7 day neonatal atrial and ventricular cardiac myocytes 
were treated for 48 hours in DMEM/F12 media supplemented with 1% ITS and 1% P/S. Cells were then 
harvested and used for immunoblotting. 
 
2.2 Tissue Isolation 
Adult atria and ventricle tissue were isolated from approximately three month old Sprague-Dawley 
rats. Similar protocol was followed for the excision of neonatal atrial and ventricular tissue. Rats were 
anesthetized with AErrane isoflurane gas (Cat. #AHN3637, Baxter) prior to surgery. The desired tissue 
was then isolated and washed in phosphate buffer saline (PBS). Both atria and ventricle were separated 
and frozen in liquid nitrogen for future use. 
 
2.3 Tissue Homogenization 
 Atria or ventricle tissue were cut into small pieces and treated with 100-500μL 1% Triton X-100 
lysis buffer. Stock lysis buffer consisted of the following: 10 mL 1% Triton X-100, 1 tablet Complete, Mini, 
EDTA-free protease inhibitor cocktail (Cat. #04693159001, Roche Diagnostics) and 1 tablet PhosSTOP 
phosphatase inhibitor cocktail (Cat. #04906837001, Roche Diagnostics). Tissue was further minced in 
solution and transferred using a 1000 μL pipette to a glass homogenizer. Tissue was disrupted to liquid 
state. After homogenization, the tissue solution was transferred to an Eppendorff tube with a glass pipette 
and sonicated for 30 seconds. Tissue lysate was placed on ice for 20 minutes then spun at 120,000 rpm 
at 4°C. The protein-containing supernatant was collected into separate Eppendorff tubes. 
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2.4 Cell Harvesting 
2.4.1 Using 1% Triton X-100 Lysis Buffer 
Medium was removed and cells washed with fresh PBS three times. Cells were then scraped 
using a rubber scraper in 1 mL PBS per 10 mm dish and collected into Eppendorff tubes. The solution 
was allowed to spin at 1500 rpm for 5 minutes at room temperature. Following this, the supernatant was 
removed and the pellet re-suspended in 100 μL of lysis buffer. The resulting cell lysate was then vortexed 
and placed on ice for 20 minutes. Again, the lysate was spun at 120,000 RPM for 5 minutes at 4°C and 
the supernatant removed. Samples were stored at -20°C. 
 
2.4.2 Using Sodium Dodecyl Sulfate (SDS) 
Media was removed and cells washed with fresh PBS three times. Cells were then scraped with a 
rubber scraper in 100 μL 2x SDS per 10 mm dish, then transferred and re-suspended in an Eppendorff 
tube. If cells were harvested from 6-well or 12-well plates, 50 μL 2x SDS was applied. The resulting cell 
lysate was boiled for 10 minutes, and then spun at 120,000 RPM for 5 minutes at 4°C. The supernatant 
was then removed and stored at -20°C for future use. 
 
2.5 Bradford Assay 
2.5.1 Standard Bradford Assay 
Standards were made with 1 μg/μL of bovine serum albumin (BSA) and double distilled water at 
concentrations of 1 μg/μL, 0.5 μg/μL, 0.25 μg/μL, 0.125 μg/μL, 0.0625 μg/μL, as well as a blank with 
double distilled water alone. Cell lysates were read at a dilution of 1:10 and tissue lysates read at a 
dilution of 1:50. 1 mL of Bio-Rad Protein Assay Dye Reagent Concentrate (Cat. #500-0006, Bio-Rad 
Laboratories) was added to 20 μL of each sample in polystyrene cuvettes. Protein concentrations were 
then read at 595 nm using a Beckman DU-640 spectrophotometer (Beckman Coulter, Brea CA, USA). 
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2.5.2 Detergent-compatible (DC) Bradford Assay 
Standards were made with 1 μg/μL of BSA and double distilled water at concentrations of 1 
μg/μL, 0.5 μg/μL, 0.25 μg/μL, 0.125 μg/μL, 0.0625 μg/μL, as well as a blank with double distilled water 
alone. Cell lysates were read at a dilution of 1:10. Protein concentrations were determined using a 
Detergent Compatible (DC) Protein Assay Kit II (Cat. #500-0112, Bio-Rad Laboratories). Reagent S (Cat. 
#500-0115, Bio-Rad Laboratories) was diluted in Reagent A (Cat. #500-0113, Bio-Rad Laboratories) at 
20 μL: 1 mL. 100 μL of this solution and 800 μL of Solution B (Cat. #500-0014, Bio-Rad Laboratories) was 
added to each sample in polystyrene cuvettes and read at 595 nm on the spectrophotometer mentioned 
above. 
 
 
2.6 Western Blotting 
Samples were diluted to the desired loading concentration using Triton X-100 lysis buffer (10 mL 
1% Triton X-100, 1 tablet Complete, Mini, EDTA-free protease inhibitor cocktail (Cat. #04693159001, 
Roche Diagnostics) and 1 tablet PhosSTOP phosphatase inhibitor cocktail (Cat. #04906837001, Roche 
Diagnostics)) and SDS. 
10% and 15% polyacrylamide gels were made from solutions consisting of double distilled water, 
30% acrylamide mix, 1.5M Tris (pH 8.8), 10% SDS, 10% ammonium persulfate, and TEMED 
(tetramethylethylenediamine). Proteins were resolved by SDS-PAGE using the Mini Trans-Blot Cell (Cat. 
#170-3989 - Bio-Rad Laboratories) for 1 hour at 100-150V. 20 μg of sample were loaded alongside a 
protein ladder. Gels were run in running buffer consisting of 25 mM Tris base, 190 mM glycine, and 0.1% 
SDS. Following separation, proteins were transferred onto either Immun-Blot polyvinylidenedifluoride-plus 
(PVDF) membranes (Cat. #162-0177, Bio-Rad Laboratories) for chemiluminescent detection or 
Immobilon-FL PVDF membranes (Cat. #IPFL00010 - EMD Millipore) for fluorescent detection, for one 
hour at 100V. Transfer of protein was done in transfer buffer consisting of 25mM Tris base, 192 mM 
glycine, and 20% methanol. The membrane was then washed in TBST consisting of: 20mM Tris base, 
137 mM NaCl and 0.1% Tween 20, three times. One of the two following protocols was then followed: 
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2.6.1 Antibody Incubation - Chemiluminescent Detection 
Post-transfer, the PVDF membrane was exposed to blocking buffer (1 g skim milk powder diluted 
in 20 mL TBST) for one hour, and then washed three times for five minutes with fresh TBST. Following 
this, the membrane was washed with primary antibody for another hour. The membrane was again 
washed three times for five minutes with fresh TBST. Finally, the membrane was probed with the 
corresponding anti-mouse or anti-rabbit secondary antibody (1:40,000) for one hour. A list of primary and 
secondary antibodies and their corresponding dilution factor is listed in Appendix A. The probed 
membrane was again washed three times for five minutes with TBST. Thereafter, 1 mL of ECL (1:1 
mixture of Western Lightning Plus-ECL Enhanced Luminol Reagent Plus to Western Lightning Plus-ECL 
Oxiding Reagent Plus (Cat. #50-904-9326, Thermo Fisher Scientific)) was added to the membrane for 
one minute. 
The membrane was then placed inside a cassette within a polypropylene sheet protector and 
brought to a dark room for development. A sheet of Diamed Western Blotting Film (Cat. #DIAFILM810, 
Diamed Lab Supplies) was placed on top of the membrane for the desired exposure time and developed. 
All dark rooms were exposed to small amounts of red light for visual assistance. 
 
2.6.2 Antibody Incubation - Fluorescent Detection 
The membrane was exposed to blocking buffer (1:1 mixture of PBS to Odyssey Blocking Buffer - 
Cat. #927-40000, LI-COR) for one hour, then washed three times for five minutes with fresh TBST. 
Following this, the membrane was washed with primary antibody for another hour. The membrane was 
again washed three times for five minutes with fresh TBST. Finally, the membrane was probed with the 
corresponding anti-mouse or anti-rabbit secondary antibody (1:10,000) for one hour in light-sensitive 
containers (Cat. #MTCB1200-7BK - Diamed Lab Supplies). A list of secondary antibodies and their 
corresponding dilution factor is listed in Appendix A. The probed membrane was washed again with TBST 
three times. Thereafter, the membrane was placed onto a LI-COR Odyssey B446 Infrared Imaging 
System (LI-COR, Lincoln NE, USA) connected to Image Studio Software (LI-COR, Lincoln NE, USA). A 
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picture was scanned of the membrane at 700 nm and 800 nm channels. Exposure levels were adjusted 
and channels distinguished on Image Studio for a clear picture of the desired bands. All membranes were 
dried out following development and placed in a transparent sheet for future use. 
 
Densitometry was conducted utilizing the software ImageJ (National Institutes of Health, USA). 
 
2.7 Transfection 
Cells were plated to 12-well plates in their corresponding media overnight. If at least 60% 
confluency was reached, transfection took place. Plasmids containing promoter DNA were prepared at 
0.5 μg per 1 mL Opti-Mem media. 2 μL of Lipofectamine 2000 per 1 μg of DNA was added to the mixture 
and incubated at room temperature for 30 minutes. Before adding Opti-Mem media, media was removed 
and cells were washed with 1 mL sterile PBS. Cells were then incubated in Opti-Mem containing its 
corresponding DNA for four hours to allow for sufficient transfection of cells.  
After this period, Opti-Mem media was replaced with treatment media for 48 hours to allow the 
treatment to elicit an effect. Media was replaced every 24 hours. The supernatant of these cells was then 
collected and frozen at -20°C for future use. 
 
2.7.1 Promoter activity: syntaxin 1A and SNAP25 
Cells were transfected with one of three pEZX-PG04 vectors containing the desired promoter 
sequences: syntaxin 1A (brain) - 1050 bp long (Cat. #MPRM26278-LvPG04, Genecopeia), 
synaptosomal-associated protein 25 (SNAP25) - 1287 bp long (Cat. # MPRM14574-LvPG04, 
Genecopeia), or an “empty” vector lacking a promoter sequence. All reporter clones contain Gaussia 
luciferase (GLuc) downstream of the promoter, and the internal control, secreted alkaline phosphatase 
(SeAP) downstream of GLuc. 
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2.7.2 Plasmids - Botulinum neurotoxins 
Cells were transfected with plasmid DNA for botulinum neurotoxin A (BoNT/A), botulinum 
neurotoxin C (BoNT/C), or green fluorescent protein (GFP) as a control to determine transfection 
efficiency. BoNT/A and BoNT/C cleave SNAP25 and syntaxin 1A, respectively. After 48 hours in 
treatment media, post-transfection, a secretion assay was done on the cells, and the supernatant 
collected for enzyme-linked immunosorbent assay (ELISA) analysis. 
 
2.7.3 FOR/PMA Treatment (following transfection) 
After incubating with DNA, Opti-Mem media was replaced with DMEM/F12 media supplemented 
with 1% ITS and 1% P/S, as well as 10uM forskolin and 20 nM phorbol 12-myristate 13-acetate 
(FOR/PMA) and incubated for 24 hours. 
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Figure 8. PeZX-PG04 vector containing fused promoter sequences for syntaxin 1A or SNAP25, 
obtained from Genecopeia. All three vectors obtained from Genecopeia contain Gaussia luciferase 
(Gluc) immediately downstream of the promoter and secreted alkaline phosphatase (SEAP) downstream 
of GLuc, acting as an internal control. Promoter activity was measured as a ratio of GLuc/SEAP. An 
“empty” vector, lacking a promoter sequence, was used a negative control. 
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2.8 GLuc/SEAP Secreted Luciferase Assay 
Samples were thawed from storage at -20°C before use. The supernatant collected from cells 
transfected with a SNARE protein promoter or negative control clone were analyzed using a Secrete-Pair 
Dual Luminescence Assay Kit (Cat. #SPDA-D100, Genecopeia). Briefly, a GLuc Assay Working Solution 
was prepared to dilute the enzyme stimulating luminescence of Gaussia luciferase (Substrate GL-S). This 
buffer was comprised of a 1:10 dilution of Genecopeia's stock GL-S Buffer in double distilled water. 
Substrate GL-S was then diluted 1:100 in the buffer, protected from light, and incubated for 25 minutes at 
room temperature. 10 μL of each sample were then added to luminometer tubes in duplicates and the 
corresponding samples read using a EG&G Berthold - Lumat LB 9507 luminometer (Berthold 
Technologies GmbH & Co. KG, Bad Wildbad, Germany). The luminometer’s automatic injector was then 
primed with the GLuc Assay Working Solution and set at the following parameters: 100 µL of injection, 60 
seconds delay, 2 seconds integration, followed by measurement of activity. 
Afterward, the collected supernatant was heated to 65°C for 15 minutes, and cooled to 4°C in 
preparation for SeAP protocol. SeAP Assay Working Solution was prepared to dilute the enzyme 
stimulating luminescence of SeAP (Substrate AP). This solution was diluted 1:10 using Genecopeia's 
stock AP Buffer in double distilled water. Substrate AP was diluted 1:100 in ithe buffer, protected from 
light, and incubated for 5-10 minutes at room temperature. 10 μL of each sample were then added to 
luminometer tubes and read using the EG&G Berthold - Lumat LB 9507 luminometer. The luminometer’s 
automatic injector was then primed with the SeAP Assay Working Solution and set at the following 
parameters: 100 µL of injection, 5 minutes delay, 2 seconds integration, followed by measurement of 
activity. 
SeAP was used to remove the impact of transfection efficiency variation across multiple cell 
types. Thus, the analysis of luciferase readings were graphed as relative lights units (RLU) of 
GLuc/SEAP. 
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2.9 ANP Secretion Assay 
Myocytes were plated into either 6 well plates or 12 well plates post-isolation. They were then 
treated for 48 hours in their corresponding media to allow cells to equilibrate with their environment. Cells 
were washed with PBS and treated with 1 mL of Krebs Ringer Bicarbonate (KRB) buffer (129mM NaCl, 
4.8 mM KCl, 1.2 mM KH2PO4, 2.4 mM MgSO4, 2.5 mM CaCl2, 5mM NaHCO3, 10mM HEPES, and 0.1 g 
of bovine serum albumin, pH 7.4) with or without 30 nM endothelin-1 (ET-1) for 2 hours. ET-1 was used to 
stimulate ANP secretion in the treated myocytes. Post-treatment, the supernatant was removed and 
frozen at -20°C.  
 
2.10 ELISA Assay 
Supernatant collected from the ANP secretion assay was thawed from -20°C and probed using a 
pre-coated ELISA kit (Cat. #EK-005-24, Phoenix Pharmaceuticals, Burlingame CA, USA) targeted for 
atrial natriuretic peptide (1-28 amino acids, specific for rat and mouse). The kit utilizes the principles of a 
competitive ELISA. The assay is standardized using standard peptide provided by the company and 
graphed using a four parameter logistic curve. The plate itself is pre-coated with secondary antibody 
which binds to the Fc component of the kit’s primary antibody. The antigen-binding component of the 
primary antibody (Fab) is then free to bind to either the biotinylated peptide or the targeted peptide, ANP. 
When the biotinylated peptide interacts with streptavidin-horseradish peroxidase (SA-HRP), these 
samples undergo an observable change in colour from clear to yellow depending on the proportion of 
biotinylated peptide to targeted peptide bound. Absorbance was read using a DTX 880 Beckman Coulter 
96-well plate Multimode Detector (Beckman Coulter, Brea CA, USA) at a wavelength of 450nm. The data 
obtained was then analyzed using ElisaAnalysis.com’s on-line software at: http://elisaanalysis.com 
(Version 3.2) (Leading Technology Group, Australia). 
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2.11 Statistical Analysis 
Each sample is equivalent to experiments done on cells collected from a litter of 15-20 rat pups. 
Sample size is therefore representative of the amount of litters used in the experiment. 
Data was analyzed using Microsoft Excel (Microsoft, Redmond WA, USA) and graphed as mean 
± standard error of the mean (SEM). Statistical analysis was conducted using IBM SPSS Statistics 
(Armonk NY, USA) software using one-way analysis of variance (ANOVA), followed by Tukey's post-hoc 
test. Significance was generally accepted at *p<0.05 and **p<0.01. 
All statistically analyzed immunoblotting data are representative of at least three separate trials. 
Each trial of luciferase data is representative of the average of two biological replicates and two technical 
replicates. Graphed luciferase data is representative of at least three separate trials. 
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Results 
3.1 Characterization of SNARE proteins involved in constitutive secretion 
Natriuretic peptides are secreted via a regulated or constitutive pathway. Regulated secretion is 
stimulated by mechanical stretch and/or stimulation by neuroendocrine factors, while constitutive 
secretion encompasses the direct synthesis and secretion of the protein. The SNARE proteins involved in 
the regulated secretion of ANP have been characterized by previous groups (Peters et al. 2006; Ferlito et 
al. 2010) but the SNARE proteins involved in constitutive secretion have not yet been identified. Out of 
the SNARE and SNARE-associated proteins identified to be involved in constitutive secretion by Gordon 
and colleagues (2010), I chose to characterize the three SNARE proteins syntaxin 5A, syntaxin 18 and 
SNAP29. These proteins were chosen based on their role in different components of the vesicle 
trafficking pathway: syntaxin 5a for anterograde transport from the ER to the Golgi, syntaxin 18 for 
retrograde transport from the Golgi to the ER, and SNAP29 for post-Golgi to membrane transport. 
Heart tissue was isolated from neonatal rats at 1 day, 7 days, and 14 days, as well as 3 month 
old adults and homogenized with lysis buffer containing Triton X-100 detergent. Using Western blot, 
tissue lysates were probed for each SNARE protein.  In atrial tissue, syntaxin 5A levels significantly 
increased with age from 1 day (p<0.01) and 7 day (p<0.01) to adult (Figure 9a). In contrast, syntaxin 18 
and SNAP29 protein levels significantly decreased from 1 day to adult (p<0.01, p<0.05) (Figure 9b,c).  
Similar expression profiles were observed in ventricle tissue. Syntaxin 5A levels significantly 
increased in adults (p<0.01) relative to 1 day tissue (Figure 10a), syntaxin 18 significantly decreased in 14 
day and adult tissue relative to one day (p<0.05, p <0.05) and 7 day (p<0.01,p<0.01) neonatal tissue 
(Figure 10c), and SNAP29 levels remained relatively constant with age (Figure 10e). There were no 
significant changes in SNARE protein expression from 1 day to 7 day myocytes. Fibroblasts did not 
express syntaxin 5A, but displayed similar expression to myocytes for syntaxin 18 and SNAP29 (Figure 
10b,d,f).   
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Figure 9. Expression profiles of syntaxin 5A, syntaxin 18, and SNAP29 normalized to 1 day for 1 
day, 7 day, 14 day neonatal and adult atrial rat tissue. (a) There is a significant increase in syntaxin 5A 
protein levels at adult atrial tissue relative to 1 day (p<0.01) and 7 day (p <0.01) atrial tissue (n=7). (b) 
Syntaxin 18 expression levels decrease in adult atrial tissue relative to 1 day (p<0.01) atrial tissue (n=8). 
(c) SNAP29 levels display a significant decrease in adult atrial tissue relative to 1 day (p<0.05) atrial 
tissue (n=4). (d) 1 day, 7 day, 14 day and adult atrial tissue probed by Western blot for SNARE proteins 
Syntaxin 5A, Syntaxin 18, SNAP29 and loading control, GAPDH.  
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Figure 10. Expression profiles of Syntaxin 5A, Syntaxin 18, and SNAP29 normalized to 1 day for 1 
day, 7 day, 14 day neonatal and adult ventricle rat tissue. Cells are normalized to 1 day myocytes 
for 1 day, 7 day myocytes, and 7 day fibroblasts. (a) There is a significant increase in Syntaxin 5A 
protein levels in adult ventricle tissue relative to 1 day (p<0.01) (n=6). (b) Syntaxin 5A levels display a 
general increase from 1 day to 7 day ventricle myocytes, and is absent in 7 day fibroblasts (n=6). (c) 
There is a significant decrease in Syntaxin 18 protein levels from 7 day ventricle tissue to 14 day (p<0.01) 
and adult (p<0.01) ventricle tissue, and 1 day ventricle tissue to 14 day (p<0.05) and adult (p<0.05) 
ventricle tissue (n=6). (d) Syntaxin 18 levels remain relatively constant between cell types (n=6). (e) 
SNAP29 levels are relatively constant across age (n=6). (f) There are no significant changes in SNAP29 
levels across cell types (n=6). (g) 1 day, 7 day, 14 day neonatal and adult ventricle tissue as well as 1 
day, 7 day myocytes, and 7 day fibroblasts probed by Western blot for SNARE proteins syntaxin 5A, 
syntaxin 18, SNAP29 and loading control, GAPDH. 
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3.2 Characterization of syntaxin 5A, syntaxin 18 and SNAP29 during hypertrophy 
In correspondence with my hypothesis, if syntaxin 5A, syntaxin 18 and SNAP29 are indeed 
involved in the constitutive secretion pathway, this should be reflective in their response to hypertrophy. 
As the ventricle is the main site of constitutive secretion, ventricular myocytes and fibroblasts were 
isolated from trypsinized tissue and incubated for 24 hours. Post-incubation, myocytes were cultured for 
48 hours in three conditions: control medium (DMEM/F12, 1% P/S solution, 1% Insulin-Transferrin-
Selenium), control medium with 100μM phenylephrine (made in 1 mM ascorbic acid), and control medium 
with 10% FBS. Phenylephrine, an alpha-adrenergic agonist and fetal bovine serum both stimulate cell 
growth and/or contain growth factors, inducing hypertrophy in cardiac myocytes. Following treatment, 
cells were harvested and probed by Western blot. Fibroblasts were cultured for 48 hours in one of two 
conditions: control medium  (DMEM/F12, 1% P/S solution, 10% FBS) or control medium with 50ng/mL of 
TGF-β. Treatment with TGF-β stimulates the phenotypic change of fibroblasts to myofibroblasts, 
characteristic of these cells during hypertrophy and cardiac disease. 
As expected, 7 day ventricular myocytes displayed a general increase in pre-pro-ANP and pre-
pro-BNP expression levels after treatment with phenylephrine or FBS (Figure 11d,e). This homeostatic 
response is expected as an increase in natriuretic peptide secretion is a natural response to hypertrophy 
in cardiac myocytes. Surprisingly, a significant decrease in syntaxin 5A (p<0.05) (Figure 11) expression 
was observed post-drug treatment. A slight increase in syntaxin 18 (Figure 11) expression was also 
observed in cells undergoing FBS-induced hypertrophy. It is worth mentioning that there are clear 
differences in SNARE protein expression between myocytes treated with FBS versus myocytes treated 
with phenylephrine, although both were used to induce hypertrophy. Despite the significant increase in 
pre-pro-ANP (p<0.05) and general increase in pre-pro-BNP following both treatments, FBS treated cells 
generally displayed more pronounced changes in SNARE protein expression. This may be due to the 
different cellular mechanisms in which phenylephrine and FBS induce cell growth. In terms of SNAP29, 
expression levels were approximately the same (Figure 11c). 
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Finally, syntaxin 5A and pre-pro-ANP were absent in fibroblasts in both control and drug 
treatment. The absence of pre-pro-ANP conflicts with previous studies done by Cameron and colleagues 
(2000), in which pre-pro-ANP was expressed in sheep cardiac fibroblasts after treatment with TGF-β. Our 
findings suggest that pre-pro-ANP is not secreted in rat cardiac fibroblasts during hypertrophy (Figure 
11d). Pre-pro-BNP is expressed in fibroblasts but does not change with transformation to myofibroblasts 
(Figure 11e). Although syntaxin 18 and SNAP29 were expressed in fibroblasts, they did not display any 
significant changes in protein expression between control cells and those treated with TGF-β (Figure 
11a,b). 
The biologically active form of ANP is cleaved on the membrane of the cardiac myocyte by the 
serine protease, corin (Rushkoaho 2003). To corroborate that the increase in pre-pro-ANP levels 
(observed by Western blot) within the cell corresponds with an increase in ANP levels outside the cell, a 
secretion assay and competitive ELISA were used. 7 day ventricular myocytes were treated with either 
1% insulin-transferrin-selenium (ITS) as a control or 10% FBS to induce hypertrophy. Cells were then 
treated with 30 nM endothelin-1 to stimulate natriuretic peptide secretion. As predicted, an increasing 
trend in ANP secretion is observed in FBS treated cells (Figure 12), similar to the increase seen in pre-
pro-ANP levels by Western blot (Figure 11d). This increase is even more pronounced in cells treated with 
endothelin-1 (Figure 12).  
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Figure 11. Expression profiles of syntaxin 5A, syntaxin 18, SNAP29, pre-pro ANP, and pre-pro BNP 
normalized to control groups for 7 day neonatal ventricular rat cardiac myocytes treated with 
100μM phenylephrine or 10% fetal bovine serum, and 7 day neonatal ventricular rat cardiac 
fibroblasts treated with 50 ng/mL TGF-β.  Cells were treated for 48 hours with their corresponding 
treatment (n=3). (a) There is a significant decrease in syntaxin 5A levels following treatment with 
phenylephrine (p<0.05) or FBS (p<0.05) (n=3). An absence of syntaxin 5A expression is observed in 
fibroblasts. (b) A general increase in syntaxin 18 is observed in FBS-treated myocytes. No significant 
changes are observed in fibroblasts treated with TGF-β relative to control fibroblasts. (c) There are no 
significant changes in SNAP29 levels between control cells and their corresponding treatments. (d) With 
both FBS (p<0.05) and phenylephrine (p<0.05) treated myocytes, a significant increase is observed in 
pre-pro ANP levels (n =3). An absence in expression is displayed in fibroblasts. (e) A general increase in 
pre-pro BNP levels is observed following treatment with phenylephrine or FBS. Pre-pro BNP levels do not 
change significantly in fibroblasts with TGF-β treatment. (f) 7 day ventricular myocytes treated with ITS 
(control), phenylephrine or FBS and 7 day fibroblasts treated with FBS (control) or FBS and TGF-β 
probed by Western blot for SNARE proteins syntaxin 5A, syntaxin 18, SNAP29, pre-pro-ANP, pre-pro-
BNP and loading control, GAPDH. 
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Figure 12. ANP secretion in 7 day control and hypertrophy-induced rat ventricular myocytes 
treated with Krebs-Heinslett Buffer (KRB) and KRB supplemented with 30 nM endothelin-1 (ET-1). 
Cells were treated with ET-1 for 48 hours. Myocytes were treated with 1% insulin-transferrin-selenium 
(ITS) or 10% fetal bovine serum (FBS) to induce hypertrophy (n=3). An increasing trend was seen in both 
FBS treated groups relative to their corresponding controls. A more pronounced increase was observed 
in cells treated with ET-1, a potent stimulator of natriuretic peptide secretion.  
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3.3 Characterization of syntaxin 1A and SNAP25 expression 
In 2006, Peters and colleagues were the first to identify the presence of two SNARE complexes in 
rat atrial myocytes associated with ANP secretion: one found in both neonates and adults, and another 
found solely in adults, consisting of syntaxin 1A and SNAP25. The presence of a SNARE complex 
already established in both neonatal and adult myocytes brings into question the importance of a 
secondary SNARE complex. This said complex must thus have an important age-dependent function that 
has not yet been brought to light. Before studying the functional role of syntaxin 1A and SNAP25, I first 
characterized their expression profiles in the atria and ventricle to obtain an idea of their distribution in rat 
cardiac tissue.  
Using immunoblotting, atrial and ventricular myocytes isolated from 1 day and 7 day old rats, as 
well as tissue isolated from 14 day and adult rats were probed for syntaxin 1A and SNAP25. A general 
increase was observed in syntaxin 1A protein levels in 14 day and adult atrial tissue relative to 1 day and 
7 day myocytes. Syntaxin 1A was also present in the ventricle but did not significantly change (Figure 
13a). SNAP25 protein levels were only detected in adult atrial tissue, but not in ventricle tissue (Figure 
13b). Pre-pro-ANP was found to significantly increase with age as predicted in the atria, although levels 
were too low in the lysates of 1 day and 7 day myocytes to be detected via Western blot. In the ventricle, 
pre-pro-ANP levels were too low to be detected in both cells and tissue (Figure 13c). This is expected as 
the atrium is the main site of natriuretic peptide synthesis at normal physiological states. These trends 
were inferred from a sample size of one. As so, these findings would have to be replicated to observe any 
significant changes. 
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Figure 13. Expression profiles of syntaxin 1A, SNAP25, and pre-pro ANP in atria and ventricle, 
normalized to 1 day for 1 day and 7 day myocytes, and 14 day and adult rat tissue.  (a) There is a 
general increase in syntaxin 1A protein levels in 14 day and adult atrial and ventricular tissue relative to 1 
day and 7 day atrial and ventricular myocytes (n=1). (b) SNAP25 protein is observed in adult atrial tissue 
alone. SNAP25 levels are absent in both ventricular myocytes and ventricle tissue (n=1). (c) There is a 
general increase in pre-pro-ANP levels in 14 day and adult atrial tissue relative to 1 day and 7 day atrial 
myocytes. Pre-pro-ANP is not observed in ventricle myocytes and tissue (n=1). (d) 1 day, 7 day 
myocytes, and 14 day, adult tissue from both atria and ventricle probed by Western blot for SNARE 
proteins syntaxin 1A, SNAP25, pre-pro-ANP and loading control, GAPDH (n=1). 
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3.4 Transcriptional activity of syntaxin 1A and SNAP25 in atrial and ventricular cells 
After characterizing the expression profiles of syntaxin 1A and SNAP25, I also endeavoured to 
look into the transcriptional activity of their corresponding genes. Comparing promoter activity to protein 
expression profiles may provide insight into the regulation of syntaxin 1A and SNAP25 in both the atria 
and ventricle. Furthermore, the identification of chamber-specific differences could also be suggestive of 
their role in natriuretic peptide secretion. 
 Primary atrial and ventricular myocytes were isolated from 1 day and 7 day neonatal rats and 
transfected with plasmid DNA containing the two SNARE’s corresponding promoters. A secreted 
luciferase assay was used to measure transcriptional activity. Syntaxin 1A displayed no significant 
changes in promoter activity between atrial and ventricular myocytes, and across 1 day to 7 day 
myocytes. There were also no significant changes in SNAP25 promoter activity between atria and 
ventricle in 7 day myocytes. However, SNAP25 promoter levels in 7 day atrial and ventricular myocytes 
were significantly lower than 1 day atrial myocytes (p<0.01, p<0.01). In both atria and ventricle, syntaxin 
1A promoter activity doubles that of SNAP25 (Figure 14a). 
In addition to primary myocytes, two cell lines were used to study the transcriptional activity of 
syntaxin 1A and SNAP25: HL-1 cells were used to study promoter activity in atrial cells, while H9c2 cells 
were used to study promoter activity in ventricular cells. The immortalized HL-1 cell line is obtained from 
an atrial tumour, while the H9c2 cell line is obtained from the ventricle of the embryonic rat heart 
(Parameswaran et al. 2013). These cell lines are primarily used because they share similar properties 
and phenotypes to cardiac myocytes.  
Transfected HL-1 and H9c2 cells displayed similar trends to their primary cardiac myocyte 
counterparts in terms of relative syntaxin 1A to SNAP25 activity. Syntaxin 1A displayed two-fold greater 
promoter activity when compared to SNAP25. In terms of SNARE-specific trends, however, there were no 
significant changes. No significant differences were observed in syntaxin 1A and SNAP25 promoter 
activity relative to MIN6 cells (Figure 14b). 
53 
 
 
Figure 14. Transcriptional activity of syntaxin 1A and SNAP25 in 1 day and 7 day neonatal atrial 
and ventricular myocytes, HL-1 and H9c2 cell lines. Expression of syntaxin 1A and SNAP25 was 
determined using secreted luciferase reporter genes normalized to an empty vector. MIN6 cells were 
used as a positive control (n=3). In all cells studied, with the exception of MIN6, syntaxin 1A displays 
greater promoter activity compared to SNAP25. (a) There were no significant differences in syntaxin 1A 
promoter activity between atrial and ventricular myocytes. There were also no significant differences in 
SNAP25 promoter activity between atria and ventricle. However, SNAP25 promoter levels were 
significantly lower in both atrial and ventricular myocytes than the corresponding promoter activity in 1 
day atrial myocytes (p<0.01, p<0.01) (n=3).(b) Furthermore, no significant differences in syntaxin 1A and 
SNAP25 are observed across the two cell lines, HL-1 and H9c2 (n=3).Similar promoter activity is 
observed for both syntaxin 1A and SNAP25, as MIN6 cells used in this study as a positive control.  
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3.5 Effects of BoNT/A and BoNT/C on SNARE protein expression and ANP secretion 
To investigate the functional importance of syntaxin 1A and SNAP25 in atrial natriuretic peptide 
secretion, botulinum neurotoxins were used to cleave the above-mentioned SNARE proteins. 7 day 
neonatal atrial and ventricular cardiac myocytes were isolated and transfected with plasmid DNA for 
BoNT/A and BoNT/C, cleaving SNAP25 and syntaxin 1A, respectively. Cells were stimulated with 30 nM 
endothelin-1 to increase natriuretic peptide secretion. ANP levels were then measured using ELISA kits 
and the cell lysate probed using Western Blotting. 
As this assay was only conducted once, no significant trends were extracted. The general trends 
were as follows: Relative to GFP control cells, cells transfected with BoNT/C, which cleaves syntaxin 1A, 
did not result in decreased ANP levels, nor did this pattern change with treatment of endothelin-1. In 
contrast, BoNT/A, which cleaves SNAP25, resulted in a decrease in ANP secretion in both atria and 
ventricle, with the exception of the atria control group. In ventricle cells, this decrease was further 
pronounced, relative to the GFP control group, in cells treated with endothelin-1 (Figure 15a). 
Immunoblotting analysis revealed that syntaxin 1A was indeed cleaved by BoNT/C in the atria relative to 
the control group transfected with GFP alone. In contrast, ventricular cells treated with BoNT/C did not 
display a decrease in syntaxin 1A levels (Figure 15b). SNAP25 levels were not detectable in 7 day 
myocytes using immunoblotting. Pre-pro-ANP levels also decreased in both atrial and ventricular 
myocytes treated with BoNT/A and BoNT/C, relative to the GFP control group (Figure 15c).  
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Figure 15. BoNT/A and BoNT/C decrease ANP secretion and pre-pro-ANP levels in 7 day atrial and 
ventricular rat myocytes. Cells were treated with Krebs-Heinslett Buffer (KRB) or KRB supplemented 
with 30 nM endothelin-1 (ET-1) for 48 hours (n=1). (a) A decrease in ANP secretion is observed in both 
atrial and ventricular myocytes treated with BoNT/A relative to GFP control cells, excluding atrial 
myocytes treated with KRB alone. Cells treated with ET-1 display a more pronounced decrease in ANP. 
No changes are observed in ANP secretion for both atrial and ventricular myocytes treated with BoNT/C 
relative to GFP control cells. (b) A decrease in syntaxin 1A expression is observed in 7 day myocytes 
treated with BoNT/C relative to GFP control cells. (c) Pre-pro-ANP levels decrease in 7 day myocytes 
treated with BoNT/C and BoNT/A relative to GFP control cells. (d) 7 day atrial and ventricular myocytes 
transfected with GFP, BoNT/A and BoNT/C then treated with KRB or KRB supplemented with ET-1, 
probed by Western blot for SNARE proteins syntaxin 1A, SNAP25, pre-pro-ANP and loading control, 
GAPDH (n=1). 
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3.6 Effect of FOR/PMA treatment on syntaxin 1A and SNAP25 transcriptional activity  
As a follow-up to David Boyce, one of the former members of the Tsushima lab, I also 
investigated the importance of the CRE element in SNAP25 promoter activity. Using truncated promoters, 
David was able to display that the minimal promoter length for SNAP25 contains the CRE element and 
TATA box. As a follow-up study, I tested the importance of the CRE element by stimulating 7 day 
myocytes with 10uM forskolin and 20 nM phorbol 12-myristate 13-acetate (PMA). These compounds 
stimulate cAMP and PKA respectively, both of which are implicated to increase downstream binding of 
CREB to CRE. Treatment protocol was replicated from Shimada and colleagues (2007) who used 
FOR/PMA to stimulate the transcriptional activity of truncated SNAP25 promoters in ovarian cells. 
 In 7 day atrial and ventricular myocytes, there were no significant changes in syntaxin 1A and 
SNAP25 transcriptional activity following FOR/PMA treatment.  SNAP25 promoter levels were noted to be 
significantly lower than syntaxin 1A promoter levels in atrial control myocytes. Although conducted on a 
sample size of three, no remaining significant changes were observed across treatment groups (Figure 
16). 
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Figure 16. Transcriptional activity of syntaxin 1A (STX1A) and SNAP25 in 7 day ventricular rat 
myocytes treated with 10 µM forskolin and 20 nM phorbol 12-myristate 13-acetate (FOR/PMA) for 
24 hours. SNAP25 promoter levels were noted to be significantly lower than STX1A promoter levels in 
atrial control myocytes (p<0.05) (n=3). However, no significant differences were observed in the 
remaining transfected cells post-treatment or between chambers. 
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Discussion 
4.1 Role of syntaxin 5A, syntaxin 18, and SNAP29 in the constitutive secretion of ANP 
and BNP 
The SNARE proteins I chose to investigate in the constitutive secretion of ANP and BNP were 
syntaxin 5A, syntaxin 18, and SNAP29. Syntaxin 5A was previously found to be important in the 
anterograde transport of peptides from the ER to the Golgi (Dascher et al. 1994), syntaxin 18 was 
previously found to be important in retrograde transport from the Golgi to the ER (Iinuma et al. 2009), and 
SNAP29 was previously found to be important for post-Golgi to membrane transport (Su et al. 2001). 
Characterization of these SNARE proteins in atrial and ventricular tissue reveal expression 
patterns consistent with my original hypotheses (Figures 9 & 10). I expected that with an increase in pre-
pro-ANP and pre-pro-BNP, observed with age, I would see a corresponding increase in syntaxin 5A, due 
to an increase in anterograde transport, a decrease in syntaxin 18, due to a decrease in retrograde 
transport, and an increase in SNAP29 due to an increase in vesicle traffic to the membrane. I 
hypothesized that increased natriuretic peptide secretion would result in the up-regulation of SNARE 
proteins involved in anterograde transport, as more vesicles would be required for natriuretic peptide 
secretion. In addition, less vesicle degradation would occur, resulting in decreased expression of the 
SNARE proteins involved in vesicle recycling and retrograde transport. 
An age-dependent increase in syntaxin 5A expression as well as a decrease in syntaxin 18 
expression was observed in atrial and ventricular tissue. SNAP29, on the other hand, displayed a 
decrease in atrial expression and no significant changes in the ventricle (Figures 9 & 10). There were also 
no significant differences in SNARE protein expression between atria and ventricle. This is contrary to 
what I would expect as the ventricle is the main site of constitutive natriuretic peptide secretion (Bloch et 
al. 1986). Thus, I would expect to see greater levels of syntaxin 5A and SNAP29, and lower levels of 
syntaxin 18 in the ventricle. The similarity in protein expression between the two chambers suggests that 
these three SNARE proteins are not involved in the constitutive secretion of ANP and BNP. 
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The expression of syntaxin 5A, syntaxin 18, and SNAP29 in ventricular myocytes was similar to 
that of the ventricle tissue. However, the degree of change in SNARE protein expression from 1 day to 7 
day myocytes is small (Figure 10). It is important to keep in mind that the heart is composed of 
approximately 2/3 cardiac myocytes while the majority of the non-myocyte population consists of cardiac 
fibroblasts (Banerjee et al. 2007), and although the small change in SNARE protein expression does not 
exemplify the overall trend, this is but only a fraction of the total volume of myocytes in the heart. The 
absence of syntaxin 5A in fibroblasts suggests that this SNARE is not involved in ANP secretion within 
neonatal fibroblasts. However, syntaxin 18 and SNAP29 are both present (Figure 10b,d,f). 
In our model of heart disease, hypertrophic myocytes and myofibroblasts did not display the 
exaggerated trends I predicted, but rather the opposite trends. Syntaxin 5A levels decreased, syntaxin 18 
levels increased, and SNAP29 levels did not significantly change. These changes correlate with an 
increase in pre-pro-ANP and pre-pro-BNP in cardiac myocytes (Figure 11). An increase in ANP secretion 
post-treatment with fetal bovine serum was verified using an ANP-targeted ELISA (Figure 12). During 
hypertrophy, a phenomenon termed fetal gene reprogramming takes place. As indicated in section 1.1.5, 
this phenomenon is characterized by a switch in energy metabolism from carbohydrates to fats. Genes 
characteristic of the fetal register are expressed and adult genes are turned off (Rajabi et al. 2007). While 
the molecular mechanisms behind this phenomenon are not completely understood, epigenetics (i.e. 
methylation), transcriptional regulation, endoplasmic reticulum (ER) stress and reactive oxygen species 
(ROS) are some of the many factors suggested in regulating the re-expression of these fetal genes (Vo 
and Hardy 2012).  
I propose that the opposite trends in syntaxin 5A, syntaxin 18 and SNAP29 protein expression, 
observed with fetal bovine serum or phenylephrine treatment, may be due to fetal gene reprogramming. 
The genes responsible for the normal expression of these SNARE proteins are turning “off" or switching 
functions as a result of fetal genes turning on (Nakagawa et al. 1995). If this is the case and the genes 
encoding these SNARE proteins are being turned “off”, these genes are likely “adult” genes, suggesting 
that the traditional expression of these SNARE proteins is not vital to the constitutive secretion of ANP 
and BNP during fetal bovine serum or phenylephrine-induced hypertrophy. 
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The reason SNAP29 levels do not change with hypertrophy or age may be because the SNARE 
protein has multiple trafficking functions. In mast cells, SNAP29 is shown to localize at both the cytosol 
and membrane assisting with phagocytosis (Wesolowski et al. 2012). In neurons, SNAP29 localizes at 
the synapse and regulates the disassembly of the SNARE core complex (Pan et al. 2005). Other studies 
implicate SNAP29 to be localized to intracellular membrane structures within the cell during endocytic 
recycling of membrane receptors (Rapaport et al. 2010). A recent study done by Kang and colleagues in 
2011 studied the function of SNAP29 in C. elegans and found that the protein is most likely involved in 
the fusion of Golgi vesicles to the recycling endosome. This same group also suggests that SNAP29 
plays a role in secretion from intestinal cells. Despite all this, the role of SNAP29 within the cardiac 
myocyte has not previously been characterized. As a result, its function can only be inferred from 
previous studies. If SNAP29 is solely involved in the endosomal recycling pathway within the cardiac 
myocyte, it is not surprising that the trends observed to do not correlate with pre-pro-ANP or pre-pro-BNP 
levels within the cell. Instead, this post-Golgi SNARE may hold multiple trafficking functions within the 
cardiac myocyte which may or may not include the constitutive secretion of ANP and BNP. Further 
experiments would have to be conducted to test its functional importance. 
Finally, syntaxin 5A and pre-pro-ANP were found to be absent in fibroblasts, in both control and 
after drug treatment (Figure 11). This suggests that syntaxin 5A may not play a role in the constitutive 
secretion of ANP and BNP in fibroblasts. However, the absence of pre-pro-ANP conflicts with previous 
studies done by Cameron and colleagues (2000), in which ANP was expressed in sheep cardiac 
fibroblasts after treatment with TGF-β. My findings could suggest that ANP is not secreted from rat 
myofibroblasts, or it could be the case that the dosage of TGF-β was not high enough to stimulate 
transformation of fibroblasts to myofibroblasts. The study conducted by Cameron and colleagues (2000) 
was also conducted on adult animals, while my study was conducted on neonates. A possible explanation 
for this discrepancy may be that there are changes to natriuretic peptide secretion from fibroblasts with 
age. In contrast to pre-pro-ANP and syntaxin 5A, pre-pro BNP, syntaxin 18 and SNAP29 levels were 
expressed in fibroblasts (Figure 11). Expression levels for all three proteins remained the same post-
treatment. It may be possible that syntaxin 18 and SNAP29 assist in the trafficking of pre-pro-BNP, but 
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because their expression levels do not change with myofibroblast transformation, it is likely that syntaxin 
18 and SNAP29 play other roles in vesicular trafficking within the cell. 
There were no significant changes in syntaxin 5A, syntaxin 18 and SNAP29 expression between 
atria and ventricle. Furthermore, the expression of these three SNARE proteins post-treatment with fetal 
bovine serum or phenylephrine was opposite to the trends I expected. Taken together, my observations 
provide evidence towards the conclusion that these three SNARE proteins do not play a role in the 
constitutive secretion of ANP and BNP, and may be important in another protein trafficking pathway within 
the cardiac myocyte. 
 
4.2 Role of syntaxin 1A and SNAP25 in regulated ANP secretion 
The purpose of studying the transcriptional activity and expression profiles of syntaxin 1A and 
SNAP25 was to gain some insight on the chamber-specific role these two SNARE proteins play in the 
exocytosis of ANP. Having previously been suggested to form a complex important in ANP secretion 
(Peters et al. 2006), defining the age-dependent expression profiles of syntaxin 1A and SNAP25, and 
furthermore, the transcription of their corresponding genes could assist in suggesting a functional role for 
these SNARE proteins. Looking at chamber-specific differences may also provide insight into the 
localization of these SNARE proteins within the heart. 
4.2.1 Chamber-specific trends in transcriptional activity and protein expression  
The findings from my experiments confirm the discovery of Peters and colleagues (2006) that 
syntaxin 1A and SNAP25 are expressed at higher levels, if not solely in the adult atria compared to 
neonates. This increase corresponds with an increase in pre-pro-ANP levels in adult atrial tissue (Figure 
13). Although there is little to no protein expression in neonates, promoter activity for both syntaxin 1A 
and SNAP25 is observed in both 1 day and 7 day atrial myocytes (Figure 14a).  
Compared to MIN6 cells, our positive control which has been shown in previous studies to 
express both syntaxin 1A and SNAP25 (Ohara-Imaizumi et al. 2004), less promoter activity is observed in 
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primary neonatal myocytes. With this in mind, it is conceivable that the downstream peptide synthesis of 
syntaxin 1A and SNAP25 may be too low to significantly be detected via immunoblotting. If protein 
synthesis is indeed relative to transcriptional activity, then the absence of SNAP25 expression in the 
neonatal atria can also be explained relative to the expression of syntaxin 1A (Figure 13d), as syntaxin 1A 
transcriptional activity is approximately twofold greater than SNAP25 (Figure 14a).  
In the ventricle, syntaxin 1A levels increase in 14 day and adult tissue relative to 1 day and 7 day 
neonatal myocytes. Its correlation with pre-pro-ANP expression was not established as pre-pro-ANP 
levels were not high enough to be detected via immunoblotting (Figure 13c). This is presumably due to 
the ventricle’s little contribution to natriuretic peptide secretion during normal physiological conditions. 
Most natriuretic peptide secretion occurs in atrial myocytes via a readily releasable pool of granules. 
Ventricular myocytes also secrete ANP at low levels (McGrath et al. 2005). However, its contribution to 
natriuretic peptide secretion is predominately observed during chronic overload (Rushkoaho 2003).  
Based on my findings, it is feasible to imagine that syntaxin 1A may additionally be involved in the 
exocytosis and/or vesicle trafficking of other peptides in the cardiac myocyte. The high levels of syntaxin 
1A expression in the absence of pre-pro-ANP in the ventricle (Figure 13d), is suggestive that the 
synthesis of this SNARE protein may be required for other functions besides natriuretic peptide secretion. 
This would also explain why in the atria, such high amounts of protein are detected in comparison to 
SNAP25. In fact, previous studies have outlined the stoichiometric ratio of the syntaxin 1A-SNAP25 
complex to be 2:1 in neuronal cells (Lerman et al. 2000). However, the contrast in syntaxin 1A to SNAP25 
expression is so large that is likely that syntaxin 1A is required at a significant amount for other functions. 
In the neuron alone, syntaxin 1A not only functions in calcium-mediated exocytosis (Li et al. 1995), but 
also in the disassembly of the SNARE protein complex (Kee and Scheller 1996) and interacts with 
several SNARE-associated proteins besides SNAP25 including Munc proteins (Shen et al. 2007) and 
synaptotagmin (Kee and Scheller 1996). It has also been implicated to interact with potassium channels 
in pancreatic beta cells to induce glucose-stimulated insulin secretion and potassium channels on cardiac 
myocytes to regulate the excitability of the heart (Chao et al. 2011). Aside from its regulation of potassium 
channels (Chao et al. 2011, Kang et al. 2004), the function of syntaxin 1A in the cardiac myocyte has not 
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been characterized as of yet. However, its multi-faceted role in other tissues suggests that the high levels 
of syntaxin 1A expression seen in atrial and ventricular myocytes are probably required for a secondary 
function. Additional experiments would be required to demonstrate the functional role of syntaxin 1A 
within the cardiac myocyte and its stoichiometric expression when interacting with SNAP25 at the cardiac 
myocyte membrane. 
SNAP25, like pre-pro-ANP, was also undetectable in the ventricle (Figure 13b). Similar to the 
atria, SNAP25 promoter activity was not as high as syntaxin 1A in neonatal ventricular myocytes (Figure 
14a) and may have been too low to be detected with Western blot. It is worth noting, however, that 
SNAP25 expression was also absent in adult ventricular tissue (Figure 13b). These findings suggest that 
SNAP25 plays a more pivotal role in the adult atria relative to the ventricle.  
HL-1 and H9c2 cell lines were also used to study the transcriptional activity of atrial and 
ventricular cardiac myocytes. HL-1 cells, a tumor cell line derived from AT-1 atrial myocytes, are 
commonly used in the study of atrial myocytes due to its ability to maintain cardiac myocyte phenotype 
and contractility throughout serial passage. Similar to primary atrial myocytes, HL-1 cells contain ANP-
containing granules. They also display similar gene expression profiles to adult cardiac myocytes, similar 
electrophysiological properties, and receptor expression (White, Constantin and Claycomb 2004). H9c2 
cells are derived from the lower half of a 13 day embryonic rat heart mostly consisting of ventricle tissue. 
This cell line replicates but does not contract in vitro. It holds similar phenotypic and cellular properties to 
ventricular primary myocytes, but also skeletal muscle cells (Parameswaran et al. 2013). Kimes and 
Brandt (1976), who originally established the H9c2 cell line, indicate that although the cell line displays 
properties shared by both heart and skeletal muscle cells, morphologically, it is more similar to a skeletal 
muscle cell. However, studies have shown that H9c2 cells do share electrophysiological characteristics 
and respond to G-protein signalling similar to adult cardiac myocytes (Hescheler et al. 1991). 
Furthermore, when treated with hypertrophic stimuli such as ET-1 and ANGII, H9c2 cells display similar 
cell growth and up-regulation of hypertrophic genes to primary cardiac myocytes (Watkins et al. 2011). 
This makes H9c2 cells a primarily useful cell model to study cardiac myocytes in response to heart 
disease (Parameswaran et al. 2013). Due to their origins, HL-1 was used to study the transcriptional 
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activity of syntaxin 1A and SNAP25 in atrial cardiac myocytes, while H9c2 was used as a model for 
studying ventricular cardiac myocytes. 
Syntaxin 1A and SNAP25 transcriptional activity did not change across the two cell lines. Similar 
to the trends seen in primary cells, syntaxin 1A again displayed greater promoter activity (Figure 14b). As 
both HL-1 and H9c2 cells have previously been found to display characteristics of adult cardiac myocytes, 
it may be possible that the adult and not solely neonatal cells display similar levels of syntaxin 1A and 
SNAP25 promoter activity in the atria and the ventricle. This phenotype would have to be supported by 
studies done on primary adult myocytes. 
All in all, I propose that syntaxin 1A and SNAP25 form a secondary SNARE complex in neonatal 
and adult cardiac myocytes which assists with the regulated secretion of ANP. As the ventricle is the main 
site of constitutive secretion, SNARE protein levels are not as high in this chamber. I propose the 
following: Low levels of both SNARE proteins are transcribed and translated in neonatal atrial cells to 
assist with regulated ANP secretion. This explains why syntaxin 1A and SNAP25 transcriptional activity is 
observed in atrial myocytes but protein levels are low or absent. Since regulated ANP secretion occurs at 
much lower levels in the ventricle (as noted in previous studies by a lack of secretory granules (Bloch et 
al. 1986)), it is expected that the transcriptional activity and protein synthesis in this chamber would be 
significantly lower. With age, however, natriuretic peptide secretion increases from the cardiac myocyte 
(Clerico et al. 2006), increasing the demand for the SNARE proteins required in its exocytosis. The 
primary SNARE complex, consisting of syntaxin 4 and SNAP23, identified in both neonates and adults 
(Peters et al. 2006), is not sufficient enough to meet the demands of the cell. As a result, an increase in 
protein synthesis and transcription of syntaxin 1A and SNAP25 occurs to assist with the increased 
exocytosis of ANP.  
It is possible, however, that transcriptional activity does not correspond with protein synthesis. 
Though transcription may be occurring, post-transcriptional and post-translational regulation may keep 
the protein from being synthesized until required at a future time or during a particular state. Thus, it may 
be that at the neonatal stage, transcription of both syntaxin 1A and SNAP25 occurs, but the peptide 
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synthesis of syntaxin 1A solely takes place. In this case, I still propose that the secondary complex 
assists with regulated natriuretic peptide secretion, but instead of an increase in transcription as a 
response to increased ANP secretion, a post-transcriptional or post-translational mechanism occurs in 
which the previously transcribed mRNA transcript is processed into its peptide product. 
 
4.2.2 Functional significance of SNAP25 and syntaxin 1A: Use of botulinum neurotoxins 
In addition to characterizing the expression profiles and transcriptional activity of SNAP25 and 
syntaxin 1A, I also sought to investigate their functional role through the use of botulinum neurotoxins 
(BoNT). 7 day myocytes were transfected with BoNT/A and BoNT/C to proteolytically cleave SNAP25 and 
syntaxin 1A respectively. ANP secretion was then measured using an ANP-targeted ELISA to examine 
the effects of syntaxin 1A and SNAP25 proteolysis. Pre-pro-ANP levels within the cell were also 
examined using Western blot. 
My findings display that the cleavage of SNAP25 with BoNT/A (with the exception of the atrial 
control group) consistently decreases ANP secretion (Figure 15a), a finding that is slightly more 
exaggerated in both atrial and ventricular myocytes stimulated with endothelin-1. Replicates of this 
experiment would have to be conducted to make any significant conclusions, but from my observations, 
the resulting decrease in ANP secretion displays the importance of SNAP25 in ANP exocytosis. 
Unfortunately, SNAP25 protein levels were not detectable with Western blot making the efficacy of 
BoNT/A difficult to determine. Similar to the results discussed in section 4.2.1, SNAP25 expression may 
have been too low to be detected via immunoblotting.   
Although the exact localization and function of SNAP25 in cardiac myocytes remains to be 
characterized, its interaction with syntaxin 1A does not seem integral to the exocytosis of ANP, as the 
cleavage of syntaxin 1A with BoNT/C does not decrease ANP secretion (Figure 15a). Immunoblotting 
analysis, however, displays that syntaxin 1A protein levels decrease in both atrial and ventricular cells 
treated with BoNT/C relative to their GFP control groups, confirming the efficacy of the neurotoxin (Figure 
15b).  
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Cleavage of both SNAP25 and syntaxin 1A resulted in a decrease in pre-pro-ANP levels in the 
atria (Figure 15c). Pre-pro-ANP levels were too low to be detected in the ventricle. The contrasting result 
in pre-pro-ANP levels and ANP secretion in atrial myocytes treated with BoNT/C suggest a difference in 
the functional role of syntaxin 1A and SNAP25 in ANP release. 
In agreement with my proposal in section 4.2.1, the syntaxin 1A-SNAP25 complex likely assists 
with the regulated exocytosis of ANP. Evidence that syntaxin 1A and SNAP25 are not involved in 
constitutive secretion, but regulated secretion has previously been shown in constitutively secreting cell 
lines, where stimulation by these SNARE proteins resulted in a release of peptides from stored vesicles 
(Bittner et al. 1996). The reason why secretion of ANP is impaired in cells treated with BoNT/A, and not 
BoNT/C, may be because the little SNAP25 expressed in these myocytes is crucial to the SNARE 
complex involved in regulated exocytosis of ANP. This is why an even larger decrease is observed in 
ANP secretion levels for atrial and ventricular myocytes treated with both BoNT/A and endothelin-1, as 
oppose to those treated with BoNT/C. Although levels of SNAP25 are indetectable in the ventricle (Figure 
15d), I propose that the little regulated secretion occurring in the ventricle does involve SNAP25, and 
cleavage of this protein is enough to elicit an observable decrease in ventricular ANP secretion.  
Syntaxin 1A may also contribute to this complex, albeit at lower levels in neonatal cells relative to 
adult cells. Indeed, cleaving this SNARE with BoNT/C results in a decrease in pre-pro-ANP levels within 
the atrial cardiac myocyte (Figure 15c). However, this result is not extrapolated onto secreted ANP levels 
(Figure 15a). Thus, it is possible that syntaxin 1A plays a small role in the regulated release of ANP, 
although not significant enough to decrease ANP secretion. Similar to what was proposed in section 
4.2.1, it may be that syntaxin 1A plays a secondary role in vesicle trafficking within the cardiac myocyte, 
which is why its cleavage did not significantly impair the exocytosis of ANP. It is possible that the complex 
Peters and colleagues (2006) also found in neonatal myocytes consisting of syntaxin 4 and SNAP23 may 
be assisting with ANP secretion in compensation for the lack of syntaxin 1A. The functional role of 
syntaxin 1A in the cardiac myocyte remains to be completely characterized. It may be that this SNARE 
plays additional functions in vesicle trafficking, perhaps interfering with the processing of ANP pro-
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peptides in the rough endoplasmic reticulum. This would support the decrease observed in pre-pro-ANP 
levels with BoNT/C transfection (Figure 15c). 
 
4.3 Importance of CRE in SNAP25 and syntaxin 1A promoter activity 
David Boyce, a former member of the Tsushima lab, previously suggested that the CRE site and 
TATA box on the SNAP25 promoter may be essential to the transcriptional activity of this SNARE. Using 
a firefly luciferase/renilla assay, he showed that the minimum promoter length for SNAP25 transcription in 
HL-1 and H9c2 cell lines contains the CRE and TATA box elements (Figure 5). As a follow-up to this 
study, I further investigated the role of CRE in SNAP25 and syntaxin 1A transcriptional activity by 
stimulating 7 day atrial and ventricular myocytes, transfected with syntaxin 1A and SNAP25 promoters, 
with FOR/PMA for 24 hours. Forskolin and PMA are stimulators of cAMP and PKC, respectively, causing 
increased binding of downstream transcription factor CREB (cAMP-response element binding protein) to 
CRE. Treatment of cells should result in increased promoter activity of STX1A and SNAP25 (Figure 17).  
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Figure 17. Activation of CRE by forskolin/PMA through synthesis of cAMP and PKC, respectively. 
Forskolin increases cAMP within the cell, which then binds to PKA. PKA dissociates and a component of 
the protein moves into the nucleus where it phosphorylates CREB. CREB can also be phosphorylated 
downstream of PKC signalling which can be activated by phorbol 12-myristate 13-acetate (PMA). CREB 
binding stimulates transcription of target genes by binding to CRE promoter sites. 
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Contrary to what I expected, no significant changes in syntaxin 1A and SNAP25 transcriptional 
activity were observed post-treatment in both atrial and ventricular myocytes. Taking this into 
consideration, it is conceivable that the CRE element is not essential to the transcription of syntaxin 1A 
and SNAP25. The resulting element, the TATA box, may thus play an important role in the transcription of 
these genes. In mammalian cells, the TATA box is known to recruit RNA polymerase II (RNAPII) when 
TATA binding protein (TBP) is bound. TBP binds to the TATA box when in complex with transcriptional 
factors such as TFIID. Once RNAPII is recruited, the transcription of the gene can take place (Yang et al. 
2007). It has previously been shown that TATA-containing genes are highly regulated by nucleosomes, 
chromatin regulators and factors that interact with the TATA box binding protein (TBP). These genes are 
characterized as being highly responsive to environmental stressors or pressures, which explain why they 
are so meticulously regulated (Basehoar et al. 2004). Regulation of transcription factors that interact with 
the TATA box on the promoter region of syntaxin 1A and SNAP25 may then be the driving factor for their 
transcription in the cell. Perhaps increases in ANP secretion, an environmental stressor, are sensed by 
regulatory transcription elements within the nucleus of cardiac myocytes. These elements may then 
interact with TBP, regulating its binding to the TATA box, and recruitment of RNAPII in transcription of 
syntaxin 1A and SNAP25. 
It is surprising that in both atrial and ventricular myocytes, transcriptional activity post-treatment 
mirrors that of control cells. I would have predicted that atrial cells would have a higher sensitivity to 
FOR/PMA as the atrium is the predominant site of calcium-mediated exocytosis. It has been shown in 
both hippocampal neurons and pancreatic endocrine cells that elevated intracellular calcium levels 
increase binding to CRE via phosphorylation of the Ser133 site on CREB (Bading et al. 1993; Vallejo 
1994). It is postulated that Ser133 may be phosphorylated by PKA, as seen when stimulated by cAMP 
(Figure 19) or CaMKs (Ca2+/calmodulin-dependent protein kinases) which are auto-phosphorylated in the 
presence of calcium (Vallejo 1994). It is unclear, however, whether CRE is only activated in response to 
increases in nuclear calcium concentrations, or cytoplasmic calcium, as an additional promoter site in 
hippocampal neurons, SRE, is suggested to increase transcription in response to cytoplasmic calcium 
(Hardingham et al.1997). In summary, CREB-CRE binding is found to regulate the transcription of genes 
in both neuronal and pancreatic endocrine cells. It is apt that these cells are also characteristic models of 
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calcium-mediated exocytosis (e.g. neurotransmitters and insulin). It is therefore conceivable that CRE 
may be an essential component of SNARE protein transcription in cardiac myocytes, during the calcium-
mediated exocytosis of ANP. 
Despite the results seen in my experiments, the possibility that CRE is an essential element is still 
promising. It may be possible that the concentration of FOR/PMA used to treat the cells was not high 
enough to elicit a response. However, due to time constraints, a concentration assay could not be 
conducted. Treatment protocol was instead replicated from Shimada and colleagues (2007), who used 
10uM forskolin and 20 nM PMA to stimulate SNAP25 promoter activity in granulosa cells transfected with 
truncated SNAP25 promoter-luciferase constructs. Their treatment was conducted over a 4-hour span. To 
optimize treatment time for my study, a preliminary assay was conducted to test the efficacy of FOR/PMA 
at the indicated concentration for 4 hours versus 24 hours (Appendix B).  A 24 hour treatment elicited 
greater transcriptional activity in both atrial and ventricular myocytes, suggesting the continuous 
stimulation of promoter activity with time. In both time-sensitive treatments, transcriptional activity did not 
greatly change with FOR/PMA treatment. To test if this was a product of limited sample size, the 
experiment was replicated three times using the 24 hour treatment protocol. My findings, again, displayed 
no significant changes. 
Conducting a concentration assay before replicating this experiment and further looking into the 
importance of the TATA box on the SNAP25 and syntaxin 1A promoter site may prove useful in 
corroborating David’s initial findings that the CRE site and TATA box are essential elements in the 
promoter activity of these SNARE proteins. 
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Conclusions 
5.1. Syntaxin 5A, syntaxin 18, and SNAP29 are not responsible for the constitutive 
secretion of ANP and BNP, but may be constituents of the fetal gene program during 
hypertrophy. 
With age, the ER to Golgi SNARE protein syntaxin 5A increases in expression, the Golgi to ER 
syntaxin 18 decreases in expression and the expression of the post-Golgi SNAP29 does not change. My 
initial hypothesis predicted that these SNARE proteins may be important in the constitutive secretion of 
ANP and BNP in cardiac myocytes and fibroblasts. This finding would have been realized if the 
expression profiles of these SNARE proteins supported a significant increase in anterograde transport 
and decrease in retrograde transport in the ventricle relative to the atria, parallel to an increase in 
natriuretic peptide secretion seen with age. However, there were no differences in atrial and ventricular 
protein expression. With fetal bovine serum or phenylephrine treatment, syntaxin 5A, syntaxin 18 and 
SNAP29 displayed opposite trends in SNARE protein expression to what I would expect when 
constitutive secretion increases. I propose that the genes transcribing syntaxin 5A, syntaxin 18 and 
SNAP29 may be up-regulated during post-natal development, and down-regulated during fetal bovine 
serum or phenylephrine-induced hypertrophy, in conjunction with the theory of fetal gene reprogramming. 
These findings suggest that syntaxin 5A, syntaxin 18 and SNAP29 are not involved in the constitutive 
secretion of ANP and may be important in another peptide trafficking pathway. 
5.2. Syntaxin 1A and SNAP25 may assist with regulated ANP secretion in atrial and 
ventricular neonatal myocytes, then up-regulated during adulthood. 
As many of these experiments were based on a limited sample size of one, no definitive 
conclusions can be made. However, from my data I infer that syntaxin 1A and SNAP25 are transcribed in 
both atria and ventricle. Both proteins are expressed, albeit low levels, in neonatal atrial and ventricular 
myocytes to assist with the regulated exocytosis of ANP. Treatment with botulinum neurotoxins indicates 
that even small amounts of SNAP25 present in 7 day neonatal myocytes are important to the exocytosis 
of ANP. Syntaxin 1A may also interact with SNAP25 in the exocytosis of this peptide, but not enough to 
elicit a decrease in ANP secretion when the SNARE protein is cleaved. I suggest that syntaxin 1A has 
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other protein-trafficking functions, which is why its protein levels are conceivably higher than SNAP25. 
With age, the requirement of additional SNARE proteins is realized as ANP secretion levels go up. Thus, 
in adults, up-regulation of this SNARE complex is observed, mostly in the atria as this is the main site of 
regulated ANP secretion. 
5.3. The CRE site on the SNAP25 promoter may not be essential to the transcriptional 
activity the SNAP25 gene. 
FOR/PMA treatment of atrial and ventricular cardiac myocytes does not result in an increase in 
transcriptional activity suggesting that the CRE site on the SNAP25 or syntaxin 1A promoter is not a main 
regulatory element of these genes’ transcription. Further studies would need to be conducted to make 
any significant conclusions. I propose that the TATA box may play a more significant role in the 
transcription of these SNARE proteins in response to environmental stressors eliciting ANP release, such 
as an increase in pre-load in the heart. 
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Future Experiments 
6.1 Replicate experiments in adult cardiac myocytes. 
The discovery of syntaxin 1A and SNAP25 in the atria was originally observed in adult cardiac 
myocytes (Peters et al. 2010). In order to speculate about any age-dependent changes at the cellular 
level or draw any conclusions about the up-regulation of syntaxin 1A and SNAP25 transcription in adults, 
these experiments would have to be replicated in adult cardiac myocytes. Transfection of these cells with 
the promoters used in this study, stimulating with endothelin-1, then comparing adult promoter activity to 
neonatal cells may provide further insight into the importance of each SNARE at an adult age. 
Furthermore, cleaving these SNARE proteins with botulinum neurotoxins could provide evidence towards 
whether the up-regulation of syntaxin 1A protein levels, seen with age, indeed corresponds with an 
increase in regulated ANP secretion.  If a decrease in ANP levels is observed with BoNT/C treatment 
(contrary to the lack of change observed in 7 day neonates), this would provide more tangible evidence 
that syntaxin 1A is important in regulated ANP secretion when levels increase in adulthood.  
I would also aim to replicate the experiments conducted in this current study to increase my 
sample size and determine any significant changes. 
6.2 RT-PCR 
 In this study, promoter activity, protein level expression, and correlating ANP secretion levels 
were studied for both syntaxin 1A and SNAP25. Although transcriptional activity was investigated using 
the secreted-luciferase assay, I would also want to characterize the mRNA profiles of these two SNARE 
proteins in atrial and ventricular myocytes and tissue. Evaluating these two SNARE proteins at different 
sections of the protein synthesis pathway may paint a clearer picture as to where the proteins are 
regulated – post-transcriptionally, post-translationally, or at the peptide level – and whether these trends 
correlate with each other. It would also be interesting to look at the mRNA expression of syntaxin 1A and 
SNAP25 in HL-1 and H9c2 cells as gene expression in these cells are suggested to mirror that of adult 
cardiac myocytes (White, Constantin and Claycomb 2004) (Hescheler et al. 1991). 
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6.3 Transient knockdown, Conditional knockout 
 The functional role syntaxin 1A and SNAP25 play in ANP secretion was analyzed through the 
transfection of neonatal myocytes with botulinum neurotoxins, conducting an endothelin-1 stimulated 
secretion assay, and measuring ANP levels in the media with an ELISA. Although BoNT cleavage is site-
directed, and results in a decrease in the corresponding SNARE protein levels, conducting a transient 
knock down study with shRNA or siRNA constructs, would be a more effective method in observing the 
changes in ANP secretion. Stimulating these myocytes with endothelin-1 and hypertrophy-inducing 
compounds such as fetal bovine serum and phenylephrine would prove useful in studying the function of 
these SNARE proteins during heart disease. Alternatively, but more difficult, ANP secretion levels could 
be studied in transgenic mice with a conditional knockout using targeted loxP sites. Arash Bouramandi, 
an undergraduate student in the Tsushima lab, is currently characterizing the heart of syntaxin 1A-
knockout mice with the Langendorff perfusion apparatus and measuring corresponding ANP secretion 
levels during heart disease simulations (e.g.hypoxia, ischemia).  
6.4 Syntaxin 1A-SNAP25 SNARE complex: co-immunoprecipitation (coIP) 
 Syntaxin 1A and SNAP25 are mostly characterized to interact with each other in a complex. This 
complex consists of other SNARE proteins such as synaptobrevin/VAMP and SNARE-associated proteins 
such as synaptotagmin. This current study characterizes each SNARE’s promoter activity and protein 
expression individually rather than looking at the complex as a whole. Using co-immunoprecipitation, the 
amount of bound syntaxin 1A and SNAP25 can be characterized across ages, and the importance of 
each SNARE protein to the complex, substantiated in exocytosis. 
6.5 Confocal Imaging/TIRF 
 Syntaxin 1A, SNAP25 and pro-ANP can be tagged using fluorescent markers and viewed under a 
confocal microscope to define their localization in non-treated cells and cells treated with stimulators of 
ANP secretion such as endothelin-1. Using this method, we would also be able to confirm the co-
localization of these SNARE proteins with intracellular granules containing pro-ANP.  
75 
 
Using total internal reflection fluorescence (TIRF) microscopy, live-cell imaging and videos can 
also be observed. TIRF is particularly useful in observing secretion events. Contrasting the interaction of 
syntaxin 1A and SNAP25 with pro-ANP containing vesicles versus the interaction of SNAP23 and 
syntaxin 4 during exocytosis may provide insight into the rationale behind a secondary complex in adult 
myocytes. Perhaps one complex predominantly mediates exocytosis during regulated ANP release. 
Alternatively, one or both SNARE complexes may be constitutively expressed. Observing the differences 
in SNARE protein composition in atrial and ventricular myocytes could prove useful in understanding their 
function. 
6.6 Optimize concentration conditions: FOR/PMA treatment 
 Conducting a preliminary concentration assay for FOR/PMA on cells transfected with syntaxin 1A 
and SNAP25 promoters may be crucial to uncovering the importance of CRE in syntaxin 1A and SNAP25 
promoter activity. The concentration used was replicated from a study done on ovarian cells, while my 
study was done on cardiac myocytes. Replicating this study with an optimal concentration may make a 
difference in the stimulation of SNAP25 and syntaxin 1A promoter activity. 
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Appendix A: Primary and Secondary Antibodies 
 
 
Antibody Company 
Catalog 
Number 
Anti-Mouse or Anti-Rabbit 
Antibody (Ab) 
Dilution 
Factor 
Primary Antibodies 
    
Anti-syntaxin 5A Sigma WH0006811M1 Monoclonal Mouse Ab 1:1000 
Anti-syntaxin 18 SYSY 110 183 Polyclonal Rabbit Ab 1:1000 
Anti-SNAP29 Abcam ab138500 Monoclonal Rabbit Ab 1:1000 
Anti-syntaxin 19 Abcam ab94538 Polyclonal Rabbit Ab 1:1000 
Anti-syntaxin 1A Sigma S0664 Monoclonal Mouse Ab 1:1000 
Anti-SNAP25 Sigma S5187 Monoclonal Mouse Ab 1:1000 
Anti-syntaxin 4 SYSY 110 042 Polyclonal Rabbit Ab 1:1000 
Anti-SNAP23 SYSY 111 202 Polyclonal Rabbit Ab 1:1000 
Anti-ANP Millipore AB5490 Polyclonal Rabbit Ab 1:2000 
Anti-GAPDH Abcam ab8245 Monoclonal Mouse Ab 1:1000 
Secondary Antibodies 
    
anti-mouse 
   
1:40000 
anti-rabbit 
   
1:40000 
IRDye 800CW Goat  
anti-Mouse IgG LI-COR  926-32210 
 
1:10000 
IRDye 680CW Goat  
anti-Rabbit IgG LI-COR 926-68071 
 
1:10000 
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Appendix B: Optimizing FOR/PMA Treatment Time 
 
 
Appendix B.  Transcriptional activity of syntaxin 1A and SNAP25 in 7 day (a) atrial and (b) 
ventricular rat myocytes treated with 10 µM forskolin and 20 nM phorbol 12-myristate 13-acetate 
(FOR/PMA) for 4 hours or 24 hours. Exposure time to FOR/PMA was manipulated to determine if the 
effects of these compounds were time-dependent. There were no significant changes in FOR/PMA 
treated cells relative to non-treated cells with the exception of the atrial and ventricular control group at 24 
hours (n=1). 24 hour treated cells displayed slightly higher activity. Thus, 24 hours was chosen as the 
treatment time in the above experiments. 
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